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ABSTRACT
The presence of amyloid plaques is one of the hallmarks of Alzheimer's
disease (AD) brains. The plaque is an ordered, fibrous protein aggregate of which
the major component is the p protein, a 39-43 amino acid peptide. The P protein
is a normal product of the constitutive proteolytic processing of the P amyloid
precursor protein, and has been detected in the blood and CSF of healthy
individuals. Exposure to extrinsic factors such as metals or exogenous proteins
has been proposed to be a risk factor for AD.
Rodents encode for a P protein that differs from the human variant by
only three residues (R5G, Y10F, H13R) but do not form amyloid plaques. 11-28,
which has a conformation similar to 11-40 as measured by circular dichroism
(CD), and 11-28 rodent analogs were examined by CD and the effect of metals on
their conformations was examined. Unlike the human analog which undergoes
large conformational changes in the presence of zinc, the rodent analog shows
little change. The H13R mutation in the rodent sequence appears to be
responsible for the decreased interaction of the peptide with zinc.
The 3 protein also forms fibrillar aggregates in vitro according to a
nucleation-dependent mechanism. The apolipoprotein E genotype has recently
been recognized as a susceptibility factor for AD. The APOE4 allele correlates
with an earlier onset of AD and with increased amyloid deposition in the brain.
Apolipoprotein E (apoE) proteins may effect the rate of in vivo amyloidogenesis.
ApoE3 inhibits amyloid nucleation at an apoE3:p protein molar ratio of 1:1000.
ApoE4, which cannot form a disulfide dimer, is an equipotent or less potent
inhibitor. The apoE3 dimer is a significantly more potent inhibitor than apoE4.
The 22 kD receptor-binding region of recombinant apoE isoforms had an
inhibitory activity comparable to the native protein. The inhibitory activity of
apoE was further narrowed to a 19 kD variant. Finally, a Cys57 22 kD apoE3
mutant was a significantly less efficient inhibitor of amyloid fibril formation.
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Chapter 1
The Role of the 3 Amyloid Protein in Alzheimer's
Disease
Alzheimer's disease (AD) is a devastating neurodegenerative disorder
that was first described by the German physician Alois Alzheimer in 1907.1
The pathological characteristics are extracellular amyloid deposits and
intracellular neurofibrillary tangles (NFTs) that are found among dying
neurons in the brains of AD victims. 2 AD robs its victims of their most
human qualities: reasoning, memory, abstraction, and judgment. Paranoid
or delusional symptoms can often be a problem as well.3 A quote from a
translation of Alzheimer's 1907 case report illustrates the destructiveness of
the disease: "The first noticeable symptom of illness...was suspiciousness of
her husband. ...believing that people were out to murder her, [she] started to
scream loudly. ...At times she is totally delirious,...and seems to have
auditory hallucinations."4
Clinical symptoms typically begin with subtle short-term memory
problems but continue to deteriorate as the disease progresses, until the
victim can no longer function independently.5 Memory, language, and
orientation worsen until almost all cognitive function is lost. Death finally
occurs from secondary causes such as pneumonia. The time span between
the first symptoms of memory loss to death is ten years on average.
However, patients may live anywhere from two to twenty years in an
increasingly dependent state.6 This disease exacts a huge emotional, physical,
and economic toll on the families of the victims and on society.
Although the disease was initially recognized by Alzheimer in a 55 year
old woman, AD is now acknowledged to be the predominant cause of
dementia in people over the age of 65. This contrasts with the traditional
view of AD which only considered progressive dementia in people younger
than 65 to be AD. Dementia in people over 65 was labeled simply as "senile
dementia" and was considered to be a normal part of aging. It was not
proposed until 1976 that AD should be redefined to include both presenile
(less than 65 years of age) and senile (over 65 years of age) dementia.6 It was
first suggested at this time that AD could pose a major public-health threat in
the future.
Currently, an estimated 4 million people in the U.S. suffer from AD.7
This large number is due both to increases in the population and to changes
in how AD is defined. AD affects predominantly older people, with more
than 95% of the patients over 65 years of age. The risk of developing AD rises
with increasing age: 1% of the population between the ages 65-74, 7% of ages
75-84, and 25% of ages 85 and older have severe dementia.6
The cost of caring for an AD patient at home approaches $50,000 a year
per patient.6 Families often are not able to provide care for relatives in the
middle or late stages of AD because they require around the clock care.
Overall, the burden that AD currently places on society is extremely high. In
1994, the annual cost for nursing home care for AD alone was estimated to be
$20 billion and the costs for home care was around $80 billion, bringing the
total annual cost of AD to approximately $100 billion dollars. 6
Unfortunately, all projections predict substantial growth in the
population at greatest risk of needing 24-hour institutional care, such as AD
patients. 8 The extension of life-spans due to medical technology will also
cause an increase in the prevalence of chronic conditions, such as AD, and is
seen by some as the failure of success. The number of people with AD is
expected to climb to 15 million in less than fifty years, placing a huge burden
on the health-care industry and added pressure on scientists to elucidate the
pathogenic mechanism of AD.
Clinical Research
The lack of a well defined disease mechanism has made it extremely
difficult to not only find a therapeutic drug, but to even diagnose the disease
in the first place. The first clinical symptoms of memory loss occur well after
the initial biological insult which is responsible for initiating the cascade of
cellular processes that signal the onset of the disease. Because doctors are
unable to diagnose the disease at its starting point, finding a way to prevent
the onset of AD will remain a challenge for some time.
There are several other diseases of dementia where the clinical
symptoms are very similar to AD such as Pick's disease, Lewy body disease,
Creutzfeldt-Jakob disease, and sometimes Parkinson's disease.4 These AD
look-alike diseases complicate matters and make a clinical diagnosis very
subjective. A definitive diagnosis of AD can only be made at autopsy.
Additionally, accurate diagnosis is difficult in the elderly. Other causes of
dementia such as multi-infarct dementia (caused from atherosclerosis),
overmedication, and depression become common and confound the
diagnosis of AD.5 There is also debate over whether AD is a single disease or
a group of disorders manifesting similar symptoms and pathological
changes.9
There are presently several approaches used in the clinical diagnosis of
AD, and direct comparison of research findings across countries is
complicated by the lack of uniform diagnostic criteria. For example, doctors
in the U.S. are much more likely to diagnose dementia as AD than their
European counterparts, possibly due to the recent overwhelming national
awareness of AD in the U.S.4
In addition, much more emphasis has been given in the U.S. to the
establishment of valid criteria for the clinical diagnosis of AD. Guidelines for
the diagnosis of possible, probable, and definite AD have been published as
the NINCDS/ADRDA criteria and have been validated both clinically and
pathologically. 10 However, a uniform international criteria for the diagnosis
of AD needs to be implemented in order to compare and contrast studies
across borders and address the question of whether or not AD is a
heterogeneous disease.
AD Pathology
Extensive neuronal death is observed in AD. A 15% loss of total brain
weight is often a result of AD due to the considerable atrophy of the cerebral
cortex. 11 Two of the hallmarks of AD are the presence of extracellular neuritic
plaques and intracellular neurofibrillary tangles (NFTs). Neuritic plaques are
required, by definition, for the diagnosis of definite AD. 12 The plaques are
heterogeneous deposits of proteins that were initially termed "amyloid" by
the German pathologist Rudolf Virchow in 1853 who erroneously believed
them to be composed of a starch-like substance. 13 Five years later Friedrich
and Kekule demonstrated that these deposits were made of protein.9 The
extreme insolubility of the plaques prevented further determination of their
chemical nature until 1971 when Glenner and Wong first extracted the P
protein from vascular plaques using 6N guanidine HC1 and a partial N-
terminal sequence was produced.
Senile plaques are a complex, slowly evolving structure, and the time
required to generate fully formed, mature plaques may be years or even
decades. They are observed in the brain tissue of AD victims after silver
staining. The plaques exist as dark, spherical masses with a diameter of 50-100
gtm. The major component of the amyloid plaques was determined in 1984 to
be the P amyloid protein, a 39-43 amino acid peptide. 14 It was later confirmed
that the sequence of the protein found in the senile plaques was identical to
the protein found in the vascular plaques.15
The P protein is derived by proteolysis from the much larger 3 amyloid
precursor protein (APP). While the biological function of this protein is still
unknown, it was discovered in 1992 that the P protein is a normal product of
the constitutive proteolytic processing of APP in healthy individuals. 16 In
addition to the central core of amyloid, which accounts for more than 60% of
the total protein, the plaques also contain dystrophic neurites, altered glial
cells and a number of other proteins such as NAC (the Non-f-Amyloid
Component of AD), ubiquitin, apolipoprotein E (apoE), apolipoprotein J (or
"Clusterin"), interleukin-1, and al-antichymotrypsin.1 7
Along with the senile plaques, AD brain tissue is characterized by
variable numbers of NFTs which are dense, highly insoluble bundles of
abnormal fibers in the cytoplasm of neurons. Ultrastructurally, NFTs appear
as paired helical filaments (PHFs). Each filament is unbranched and 10 nm in
width. Two filaments are then twisted about each other to produce the PHF.1 8
The major component of the PHFs is not the 3 amyloid protein, but rather a
hyperphosphorylated form of the microtubule-associated protein tau.17 Tau
normally binds and stabilizes microtubules and promotes their assembly by
polymerizing tubulin. Microtubules are necessary for neurite extension and
maintenance, and for transport along axons and dendrites. NFTs occur in
several chronic diseases of the human brain.
For the most part, the distinction between normal brain aging and AD
is quantitative rather than qualitative. Most people who live into their late
seventies or eighties will have a few senile plaques and NFTs in their
hippocampus at the time of death. However, the brains of patients with
progressive dementia of the AD type usually show a marked increase in both
plaques and tangles than their age-matched controls.17
Amyloid Fibril
Three properties used to classify a substance as amyloid are birefringent
staining with Congo Red (Figure 1.1), fibrillar morphology as seen by electron
microscopy (EM), and an X-ray diffraction pattern consistent with a cross-3
fibril. Glenner proposed that the X-ray diffraction pattern of fibrils isolated
from the plaques of AD victims were very similar to the cross-0 fibril
structure observed by Pauling 19 in his studies of silk and polyalanine. 14
Figure 1.1 Structure of Congo Red.
In the cross-0 fibril model, the protein chains are extended and anti-
parallel to the adjacent chains, forming an anti-parallel P-sheet (Figure 1.2).
The 3-sheets then stack on top of each other in the fibril. The fibril growth is
in the direction of the hydrogen bonding, which is perpendicular to the sheet
stacking. Studies by Kurt Halverson and Peter Lansbury showed that the
model peptide comprising residues 34-42 of the P protein (334-42) formed
fibrils that had a similar structure to the full-length protein, as seen by X-ray
diffraction, yet differed slightly in morphology, as seen by EM.20
Since the amyloid fibrils are non-crystalline, structural studies in the
past have been limited to low resolution techniques such as EM and X-ray
diffraction. Recently, two methods, Fourier-transform infrared spectroscopy
(FTIR) and solid-state nuclear magnetic resonance spectroscopy (SSNMR),
have been modified and utilized by Peter Lansbury and coworkers in order to
create a new method for amyloid structure determination. 21-23 The method is
based on the spectral deconvolution by selective incorporation of 13C into the
peptide backbone, and has been used to study the structure of 334-42 by
measuring distances of up to 6A between twenty pairs of 13C-labeled carbon
atoms in the peptide.
Figure 1.2 Pauling's model for the cross-1 fibril.24
The Causative Role of f Amyloid in AD
Since the original isolation of the B protein from amyloid plaques in
1984, there has been a heated debate over whether the NFTs, the amyloid
plaques, or neither is the cause of AD. Some scientists do not believe that
amyloid deposition precedes the pathology of AD, but instead argue that
senile plaques are produced by the neurites in the plaque periphery as they
Fiber axis
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degenerate. However, while there is no concrete evidence of the causative
role of amyloid in AD, a great deal of research seems to indicate that the
amyloid plaques are important in the pathogenesis of AD. Based on the large
body of neuropathological, biochemical, molecular biological, and genetic
data, the "amyloid-cascade hypothesis" has been made.25 This hypothesis
assumes that AD is a disorder of APP processing which may have a number
of different causes and that results in the increased production of the P
protein. The aggregation of soluble 3 protein into amyloid fibrils then sets off
a chain of events that results in the formation of senile plaques which are
toxic to the surrounding neurons and induce the formation of NFTs,
ultimately leading to cell death.
Major support for this hypothesis came from the realization in 1988
that the earliest detectable AD-type structural change in the brains of Down's
syndrome (DS) patients, who have three copies of the APP gene and
invariably develop AD, is the appearance of diffuse protein deposits. 2 5
Diffuse plaques consist of an amorphous, largely non-fibrillar form of the P
protein that is hypothesized by some to be an immature form of senile
plaques. Additionally, studies of DS patients indicate that NFT's develop
after senile plaques have formed. 17
The considerable number of genetic causes for AD, which are discussed
further below, are associated with a common neuropathological and clinical
phenotype. The phenotype is characterized by abundant amyloid plaques in
the brain. Most experts agree that amyloid is the cause of at least some forms
of AD and that the formation of NFT's follow the formation of the plaques.3
In vitro studies also support the amyloid hypothesis. Aggregation of
the soluble 0 protein into amyloid fibrils is required in order for the 3 protein
to be toxic to a neuronal cell culture. 26 How the fibrillar P protein is toxic to
cells in not well understood. However, the accumulation of aggregated 0
protein has been associated with a local inflammatory response resulting
from the release of interleukin-10 (IL-10) and other cytokines which then
stimulate the production of al-antichymotrypsin. 25 This inflammation could
possibly be responsible for augmenting the cytotoxicity of the P protein and
the acceleration of APP processing into the 0 protein.
One observation that is often sited to disprove the amyloid-cascade
hypothesis is that the total number of amyloid deposits correlates weakly with
the presence and degree of dementia. However, a modest correlation does
exist, but a better correlate to the degree of dementia in AD is the extent of
neuritic degeneration and the degree of loss of synapses. 25
Metabolism of APP
During 1987 and 1988, a number of groups cloned and identified three
major forms of APP (695, 751, and 770).27 -32 The larger 751 and 770 forms,
which are generated by alternate splicing, contain a 56 amino acid domain in
the extracellular region that is homologous to the Kunitz family of serine
protease inhibitors (KPI) (Figure 1.3). Additionally, the 770 form also contains
a 19 amino acid insert. APP is produced in a wide variety of cell types and the
relative levels of the APP isoforms vary according to cell type. APP-695 is
particularly abundant in the brain and there is evidence that APP-751 is
produced in large amounts in brain regions involved in senile plaque
formation.33
Figure 1.3 Biogenesis of the P protein as derived from proteolysis of APP.
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After its synthesis on ribosomes, APP is translocated into the lumen of
the endoplasmic reticulum and transported through the Golgi apparatus;
some molecules go to the cell-surface. During this process, it undergoes N'-
and O'-linked glycosylation, sulfation, and phosphorylation. 34 APP is
normally processed in constitutive secretory and putative endosomal-
lysosomal pathways. Direct trafficking of [APP from the trans-Golgi network
to the endosomal-lysosomal system has been suggested, but has not been
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During its intracellular trafficking, APP may undergo one of two
alternate cleavages prior to secretion. The first cleavage of APP is within the
0 protein sequence (between Lysl6 and Leul7) by a protease that has been
termed "a-secretase" to produce a large secreted derivative and a small
membrane-associated fragment, neither of which contain the entire 0 protein
sequence nor is amyloidogenic.35 The second "P-secretase" cleavage is at the
amino terminus of the 0 protein. Subsequent cleavage by "y-secretase" results
in the production of the full-length, amyloidogenic protein. It is believed that
most APP molecules are cleaved by a-secretase and that only a small subset of
APP is processed by P- and y-secretases to release the 0 protein. 25 These
secretases have not yet been identified.
The constitutive secretion of the 0 protein raises the question of how
the putative transmembrane domain of APP is cleaved by y-secretase.
Additionally, as is evident from the isolation of the P protein from plaques
present in the brains of AD victims, there is heterogeneity in the y-secretase
site resulting in C-terminally truncated P proteins ranging from 39 to 43
amino acids in length. There are mutations in APP just outside the P protein
sequence that result in both an altered total amount of P protein as well as
altered ratios of the C-terminally truncated P proteins (discussed below). 17
Cleavage by a-secretase was originally demonstrated in cell-surface APP
molecules, but subsequent studies have shown this cleavage, in addition to P-
secretase, to also occur during intracellular exocytosis.36 P- and y- secretase
cleavages have also been demonstrated during endocytosis, with the resulting
release of the 0 protein occurring.37 These studies suggest that constitutive P
protein production occurs in a weakly acidic vesicle such as the endosome or
a late Golgi compartment and is followed by the rapid secretion of the 0
protein.
The biological function of APP has not been determined. The secreted
forms that contain the KPI domain might be involved in the regulation of
protease activity at the cell surface or in the extracellular environment. APP
may also have a role in tissue repair in the brain as it is secreted by blood
platelets and has an N-terminal amino acid sequence similar to platelet
coagulation Factor Xla-inhibitor which is involved in blood clotting.38 There
is evidence that APP promotes cell-cell and cell-extracellular matrix adhesion.
APP also promotes survival and growth of neurons in vitro.17
Genetic Research
After the identification of the 3 amyloid protein, research on AD
became much more prevalent and scientists began to study with more
intensity the contribution of genetics to the development of AD. Presently,
data indicates that AD is a heterogeneous disease that exists in two forms.
The first is the early-onset familial Alzheimer's disease (FAD), which is
hereditary, and the second is the more common late-onset AD. Late-onset
AD can be either genetic, as is the case with the inheritance of the APOE4
allele (discussed below), or "sporadic". The term sporadic is used to indicate
AD subjects with no family history of AD and does not necessarily imply a
nongenetic etiology.
Genetic dissection of late-onset AD is more problematic than early-
onset AD primarily because the disease is very common in the elderly,
especially in the 75-84 year age group. Therefore, the existence of multiple AD
cases in a given family does not necessarily indicate the inheritance of a
common genetic factor, and could be the result of chance or could be the
result of a combination of both genetic and sporadic forms of AD.
While the vast majority of AD cases are not associated with mutations,
a large number of the early-onset AD cases appear to be directly caused by
genetic mutations in the APP gene (Figure 1.4). These cases represent some of
the strongest evidence supporting a causative role of the P amyloid protein in
the pathogenesis of at least some forms of AD. There is an extraordinarily
high statistical correlation between inheriting one of these rare mutations
and developing the disease. These mutations are absent in large numbers of
unaffected individuals and have been considered by many to be sufficient to
cause the disease. Additionally, the phenotype associated with these
mutations is typical of AD both clinically and neuropathologically. It is due to
these two facts that the assumption was made that all cases of AD might be
the result of amyloid deposition.
Figure 1.4 APP mutations associated with early-onset AD.
In some families AD is inherited as an autosomal dominant trait.39
The first pathogenic APP mutation was found in a kindred with autosomal
dominant hereditary hemorrhage with amyloidosis of the Dutch type
(HCHWA-D). In this disease, a mutation in APP results in a Glu to Gln
substitution at position 22 of the 3 protein.40 Victims experience strokes after
the age of 25 with death occurring by the age of 60. In this disease there is
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cerebral amyloid angiopathy, but few AD-type amyloid plaques or NFTs are
found on autopsy. The identification of the HCHWA-D mutation was the
first demonstration that a APP mutation could result in amyloid deposition
and neurologic disease.5
Another pathogenic APP mutation was identified in a Dutch family
with both cerebral hemorrhage disease and dementia.4 1 The disease in this
family is a variant of both HCHWA-D disease and AD. There is a mutation
in this disease at codon 692 in APP that results in an Ala to Gly mutation at
position 21 of the P protein. An exhaustive screening of early-onset FAD
victims has proven these mutations to be very rare because they have never
been seen in controls and they are clearly pathogenic mutations. 5
Autosomal dominant APP mutations found in a Swedish familial
Alzheimer's disease (FAD) pedigree, in which Val is replaced by either Ile,
Phe, or Gly at position 717 in APP770, cause a marked increase in the
production of a P protein-bearing, carboxyl terminal, APP derivative. The
mutations, which were studied in human neuroblastoma cells (M17)
transfected with constructs expressing the wild-type or mutant APP, resulted
in five times more P protein in the mutant cells than in the cells expressing
wild-type APP. The mutant cell line also released six times more AP into the
medium. 39 A fourth double mutation (K670N and M671L in APP770)
produced a normal total amount of the P protein, but a greater proportion of
the variant I1-42.42 This longer variant has previously been shown to form
amyloid more rapidly than the shorter P protein variant, P1-40, in vitro.4 3
The clinical, neuropathologic, and genetic characteristics of AD
observed in subjects with APP mutations have several features in common.5
The first is that the age of onset is early, anywhere from 41-64 years of age,
depending on the specific mutation. The second is that inheritance is
dominant with complete penetration by the early sixties. No APP mutation
carrier living past the age of 67 has been reported.5 This indicates that in
every type of FAD caused by mutations in the APP gene, the genetic defects
are sufficient, but not necessary, for causing AD. Lastly, the clinical and
neuropathological features of AD caused by genetic mutations are
indistinguishable from those of non-APP mutation AD subjects.
A large step forward in AD research was made with the creation of the
first real animal model in 1995, the Athena mouse.44 This transgenic animal
has marked overexpression of an FAD-linked mutant APP gene and forms
AD-like plaques. 10  However, while the mouse possesses pathology
characteristic of AD (without NFTs), clinical symptoms have yet to be
observed.
As further evidence indicating the importance of amyloid in AD,
Down's syndrome (DS) patients are trisomic for chromosome 21 and
therefore have three copies of the APP gene. DS victims show signs of
amyloid formation in childhood and always develop early-onset AD.45 The
increase in the amount of the P3 protein produced by DS patients appears to be
responsible for the onset of the disease.
A mutation on chromosome 14, which encodes a recently discovered
membrane-associated protein, has been linked to a very early and severe form
of FAD. Victims start showing signs of the illness in their early 40's.46 S182
(or presenilin), the protein encoded by the isolated gene on chromosome 14,
was found to have five different missense mutations that altered the
predicted amino-acid sequence and occurred only in AD patients. The
primary structure of the longest open reading frame currently identified
predicts a 467 amino-acid protein with seven hydrophobic, putative
membrane-spanning domains. The function of S182 may be as a receptor,
channel protein, or structural membrane protein. Mutations in S182 that
alter its hypothetical role in the Golgi or membrane-trafficking might
enhance P protein production. 47 It appears that carriers of the chromosome
14 mutation do actually have an increased P protein secretion. 48 Another
mutation on a gene located on chromosome 1 has also been identified. 49,50
The product of this gene is a protein with homology to the protein mapped to
chromosome 14.
Finally, it was shown in 1993 that the APOE gene on chromosome 19 is
important in AD. Despite the difficulties in determining genetic causes for
late-onset AD, the APOE gene has been shown to be a late-onset AD risk
factor. 51 Scientists determined that people carrying the APOE4 allele, which
encodes one of the apoE isoforms, had a 15-fold increase in the risk for
developing late-onset AD. Three APOE alleles exist that encode proteins
differing from each other at positions 112 and 158: apoE3 (Cys-112, Arg-158),
apoE4 (Arg-112, Cys-112), and apoE2 (Cys-112, Cys-158).
A large number of genetic studies have confirmed that the inheritance
of one or two APOE4 alleles significantly increases the likelihood of
developing AD with the risk increasing with an increasing number of APOE4
alleles.51 Additionally, the age of onset of AD is decreased and the number of
amyloid plaques is increased with increasing number of APOE4 alleles. The
exact mechanism of action of apoE has not yet been determined.
In one study of familial, late-onset AD, approximately 90% of APOE4
homozygotes were found to have developed the disease by 76 years of age.51
While this leads to the conclusion that APOE4 homozygotes will almost
inevitably develop AD if they live long enough, it should be noted that the
possession of one or two copies of the APOE4 allele is neither necessary nor
sufficient for the development of AD.52 Unlike carriers of APP mutations
who have a 100% chance of developing AD, APOE4 heterozygotes and
homozygotes may live long into their eighties, nineties, or possibly to over
one hundred years of age without developing AD.
All of the evidence leads to the difficult question: How can all of the
biochemical and cellular abnormalities be reconciled into a mechanism that
will help to explain the pathogenesis of AD? In addition, while most of the
FAD types are linked to genetic mutations, the majority of all AD victims are
sporadic late-onset cases with no known genetic defects.
Therapeutic Options
Currently there is no proven therapy for victims of AD and research
into possible therapeutic options has been thwarted by the complex nature of
the disease. The pathology, which shows on a gross level the destructive
nature of AD, is only the end-point of a lengthy disease process and is far
removed from the initiating events of the disease. In addition, although the
pathology of most AD victims is similar, the causes of AD appear to be
heterogeneous. As previously mentioned, there are mutations on
chromosomes 21 and 14 that are responsible for some forms of FAD. For late-
onset AD, the APOE4 allele is a risk factor, but its presence does not guarantee
the onset of AD. The majority of all AD patients (50-60%) do not meet any of
the above criteria indicating that other loci contributing to AD remain to be
detected and mapped, or that environmental factors, such as the presence of
metals, are important.5 Even after all of the genes are located, substantial
effort will be required to understand how each susceptibility factor is
involved in AD pathogenesis.
The most ambitious efforts aim to identify probable causes and correct
them in an early stage. There are approximately 20 companies developing
AD drugs; the majority have focused on finding a way to prevent amyloid
buildup, thereby preventing the extracellular plaques from forming.
Scientists hope to use the Athena mouse to test competence of new drug
candidates. Characterization of the a-, P-, and y-secretases involved in APP
processing is also an important component of research aimed at the rational
design of anti-AD drugs.
While several companies are screening small-molecule drugs that
either facilitate clearance of p amyloid or prevent it from aggregating in the
first place, others are looking for a drugs that delay disease onset by
mimicking the proteins that protect neurons or that minimize the secondary
damage by scavenging toxic free radicals. 7
Once again, these drug candidates address biological mechanisms that
are not well understood. Additionally, they are directed at patients in the
early stages of disease which is problematic because without any reliable
diagnostic test, no one is really sure who is at risk until it is too late. Other
companies are looking for drugs that treat the symptoms of AD and are
studying genetically engineered cell implants that will deliver nerve-growth
factors to areas of the brain that have been damaged by the disease. Drugs that
attempt to boost memory and cognition are also being developed.7
AD is a complex and seemingly heterogeneous disorder that can strike
its victims in the prime of their lives. Victims of this destructive disease may
deteriorate into an increasingly dependent state for as long as 20 years until
death. AD is devastating not only to the victims, but also to the families who
are often the prime care-givers. The social and economic implications of an
ever-growing elderly population, which is expected to represent one in four
people in the U.S. within the next 40 years, are frightening.
Because of the increasing importance of AD, scientists have worked
intensely in the hope of developing new therapeutics for the disease.
However, this process has been thwarted by the inability of these scientists to
not only explain the complicated mechanisms involved in the pathogenesis
of the disease, but to also diagnose AD in its initial stages.
This thesis describes in vitro experiments that were designed to
elucidate critical factors in the pathogenesis of AD. Initially, the
conformation of the P protein and the effect of mutations on its metal-
binding properties was studied (chapter 2). The effect of apolipoprotein E
(apoE), a risk factor for late-onset AD, on the aggregation of the 0 protein was
also examined (chapter 3). Finally, through the use of molecular biology,
several isoforms of a domain of apoE that is critical to its interaction with P
protein aggregation were expressed and studied (chapter 4).
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Chapter 2
Metal-Binding Studies of the P Protein
The presence of insoluble protein deposits in the form of senile plaques
surrounded by damaged tissue is an invariant feature of AD. In addition to
genetic studies that implicate the 0 amyloid precursor protein (APP) in the
pathogenesis of AD,1,2 other studies have shown that in its insoluble fibrillar
form the 0 protein is toxic to cultured neurons.3 ,4  Families where AD
cosegregates with mutations in the gene on chromosome 21 encoding APP
have been identified. The presence of amyloid is also a central pathological
event in other diseases such as hereditary cerebral hemorrhage with
amyloidosis-Dutch type (HCHWA-D) where a mutation in the P protein
sequence is responsible for the fatal deposition of amyloid.5 Furthermore,
other higher mammals that encode for the same 3 protein develop amyloid
deposits while rodents that encode for a P protein containing three amino
acid substitutions do not form amyloid plaques.
In the absence of any significant quantity of brain derived material,
work with synthetically derived material has proven to be necessary and
important in studying the effect that a genetic mutation might have on the
processing or solubility of the precursor and the resulting fragments. A
mutation may result in a change in the proteolysis of the precursor which
could either liberate an insoluble fragment of an otherwise soluble precursor,
or cause an increase in the production of an amyloidogenic protein. A
mutation might also induce a conformational change that results in the
aggregation of that protein.
This chapter describes studies of several model peptides that examine
the effect of point mutations and the presence of metals on the secondary
structure of the 3 protein. Metal-binding studies were performed on several
peptides derived from the P protein and 3 protein analogs using circular
dichroism (CD) in order to provide information that will help to determine
the mechanism of amyloid formation.
Circular Dichroism
Circular Dichroism (CD) spectroscopy is a technique commonly used to
study the secondary structure of polypeptides and proteins in solution. CD
has become a standard tool of many protein chemists. CD spectroscopy uses
chirally polarized light comprised of left- and right-circularly polarized
components. The CD signal arises from the differential absorption of these
components in optically active molecules, and is reported in terms of
ellipticity (0) with a unit of degrees. The CD signal of an optically active
molecule most often occurs in the same region of the spectrum that it would
normally absorb in standard UV-VIS spectroscopy.
In proteins and polypeptides, amide bonds, aromatic side chains, and
disulfide bonds are all optically active. However, the signals from side chains
and disulfide bonds are much smaller than that from the backbone amide
bond. 6 The CD spectrum of proteins is primarily a result of the amide
chromophore, the most informative functionality to study because it is very
sensitive to changes in the secondary structure of the polypeptide backbone.
The environment in which a protein is studied (i.e. pH, solvent,
temperature) can have a large effect on the secondary structure of the protein.
The four major categories of secondary structure, a-helix, P-sheet, P-
turn, and random coil, each produce a characteristic CD spectrum. In an a-
helix, the carbonyls and amide groups align such that a macroscopic dipole
occurs which results in a strong positive signal at 192 nm and two negative
signals at 208 nm and 222 nm.7 The spectrum for a P-pleated sheet shows a
maximum near 198 nm and a minimum near 217 nm. However, these
transitions may shift depending on the type of 1-sheet present and its degree
of twist.7
CD data can be analyzed by a large number of techniques. The method
of Greenfield and Fasman is based on the spectra of polylysine and
polyglutamate under conditions where "pure" a-helical conformations were
obtained. The absorbance at 208 nm is used to calculate the amount of a-helix
present. 7 In the method of Morrisett, which is based on the work of
Greenfield and Fasman, the amount of a-helicity is calculated by using the
222 nm absorption. 8 It has been suggested that using the absorption at 208 nm
results in a much more accurate calculation of a-helix in the presence of P-
sheet content because there is little contribution from other structures at this
wavelength. 9 The percent of a-helical content can be calculated by the
following equations according to the methods of Greenfield and Fasman
(Equation 2.1) and Morrisett (Equation 2.2):
Equation 2.1 a-helix = ([01208 - 4,000)
(33,000 -4,000)
Equation 2.2 a-helix = ([01222 + 3,000)
(36,000 + 3,000)
Many computer programs have been written that will calculate all of
the secondary structural components in a given protein based on its CD
spectrum. One of these programs is PROSEC which calculates the component
contributions based on the CD spectra derived from crystalline proteins of
known secondary structures.10 Other programs are based on the CD spectra of
unnatural polypeptides.
Data obtained from CD spectra can be extremely useful in examining
the secondary structure of proteins. However, there are several potential
sources of inaccuracy that result from improper interpretation of the data.
Fitting programs can lead to false component calculations. Programs based on
the structures of proteins may be inadequate for small polypeptides.
Conversely, programs based on "pure" peptide structures can be inadequate
for studying protein structure because the long peptide homopolymers may
not be representative of those structures found in large proteins. The signal
produced by an a-helix is proportional to the chain length and there are few
examples of homopolymers that depict pure 13-turn structures. 1 1
Additionally, it has been shown that unless the CD spectral data extends
down to 184 nm, only the a-helical component is accurate. 12
Solution Structure of the 3 protein
The solution structure of the P protein has previously been studied by
several groups using CD spectroscopy in order to provide a better
understanding of the relationship between the accumulation of amyloid
fibrils in AD and the mechanisms involved in the aggregation of the P
protein. Barrow and Zagorski have found that the P protein adopts mixtures
of 1-sheet, a-helix, and random coil conformations in solution with the
relative ratios being strongly influenced by the solution conditions. 9 They
also found that the hydrophobic residues at the C-terminus of the 0 protein
are important in the initial stages of folding.
Helical structure was induced more readily in 11-39 with the
fluorinated alcohols trifluoroacetic acid (TFE) and hexafluoroisopropanol
(HFIP) than in P1-42. This indicated that 11-42 forms a more stable 3-sheet
structure in solution. Results also demonstrated that the 3-sheet structure
was intermolecular. At pH 4 to 7, the a-helical structure of 31-28, P1-39, and
31-42 was destabilized and the formation of 1-sheet structure in 13-42 was
concentration-dependent.
The sensitivity of the 3 protein conformation to pH suggests that it
may be produced from APP in acidic conditions such as those found in the
lysosome, and the increased 1-sheet structure in 13-42 also indicates that its
production could be more pathogenic than 31-40. 9 The tendency of the P
protein to form 3-sheet structures and subsequently aggregate at low pH has
been demonstrated. 13 These observations may be useful in elucidating the
molecular mechanism of AD.
A Mutation in the 1 Protein Causes HCHWA-D
The presence of amyloid is also a central pathological event in diseases
other than AD such as hereditary cerebral hemorrhage with amyloidosis-
Dutch type (HCHWA-D) in which there is extensive deposition of amyloid in
the blood vessels of the leptomeninges and cerebral cortex. This leads to
increased vessel deterioration and results in cerebral hemorrhages.5 The
main component of this amyloid is a 39 amino acid variant of the 3 protein
that is missing the carboxyl terminal amino acids. This variant has an E22Q
mutation in the 1 protein sequence. Previously it was proposed that this
modification alters the normal cleavage of the 3 protein at the neighboring
Lys16 - Leu17 site resulting in a cleavage along an amyloidogenic pathway.14
Increasing evidence suggests that the three C-terminal amino acids of
the 3 protein are critical to amyloid deposition.15 Therefore, APP mutations
that produce an increased ratio of 11-42 to 11-40 may be critical in the
pathogenesis of AD. However, based on this same evidence, one would not
expect the preferential deposition of the HCHWA-D analog. The existence of
deposits in the blood vessels of HCHWA-D victims indicates that the
mutation at position 22 in the 1 protein sequence is critical to its aggregation
and may result in a change in its conformation.
Previous studies have compared the conformations of the HCHWA-D
and wild-type 1 protein analogs. 16 Both peptides adopt primarily 3-sheet
structures at pH 7 under aqueous conditions by FTIR. At pH 12 only the
Dutch-type peptide possesses a significant amount of antiparallel 3-sheet
structure while the wild-type peptide shows absorptions characteristic of
unordered structures. Analysis by CD also suggests that the Dutch-type
peptide may contain a larger amount of 1-structure than the wild-type
peptide. Other studies have also shown that 3-conformation and the
formation and stability of fibrils were greatly enhanced by the single E22Q
mutation in the HCHWA-D peptide. 17
Mammalian Sequence Variants
Although a large number of species have a gene encoding APP, the
generation and deposition of the 3 protein into insoluble amyloid plaques is
largely restricted to aged primates and other higher mammals such as the
monkey, dog and bear, in addition to aged humans. 17-19 Within the 3 protein
region, the sequences for these mammals are identical to the human form of
the p protein. Rats and mice, however, encode for an APP that contains three
point mutations in the 3 protein region (Arg5Gly, TyrlO0Phe, and Hisl3Arg) as
is seen in Figure 2.1.20 Although the rodent form of the 3 protein is produced
by rat neuronal culture, amyloid deposits consisting of the rodent analog
have not been demonstrated in rats or mice.
Figure 2.1 Sequence variability in the primate and rodent 3 proteins.
It has been suggested that the amino acid substitutions that are found
in the rodent 1 protein might prevent the aggregation of the 3 protein into
insoluble plaques. While the rat and mouse variants of the 3 protein
5 10 13
Primate DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
Rodent --------G--------- F----R---- -------------------------------------------------
sequence are clearly as amyloidogenic in vitro as the human sequence,
kinetics measurements have actually demonstrated that the rodent peptide
formed a p-conformation more rapidly that the human sequence. 17 Three
dimensional structural differences have been noted between rodent and
human amyloid fibrils. These differences are reflected in FTIR and CD
spectroscopy and demonstrate that the rodent sequence has a slightly higher
content of 1-turn structure. 18  However, the human p protein sequence
remained in a P-sheet conformation at lower peptide concentrations than the
rodent analog. It is possible, therefore, that higher peptide concentrations are
required for aggregation of the rodent analog to occur in vivo.
While FTIR and CD studies show secondary structural differences
between the human and rodent p proteins, EM has demonstrated that both
types of fibrils have a similar morphology. Additionally, both show a green
birefringence under polarized light after Congo red staining. 18 The lack of
amyloid depositions in the brains of aged rats or mice cannot be ascribed to a
lowered tendency of the rodent 1 protein analogs to form insoluble aggregates
due to the in vitro studies. It may be that the rodent 1 protein does not form
amyloid plaques in vivo because the point mutations alter the proteolytic
processing of APP in a protective manner resulting in the production of non-
amyloidogenic fragments.
Effect of Metals on the Conformation of the B Protein
Exposure to certain metals such as aluminum, zinc, and copper has
been proposed to be a risk factor for the development of AD, but so far
epidemiological evidence has been inconclusive. 21 Metal ions may contribute
to the disease by causing a conformational change upon binding to the P
protein that accelerates its aggregation. Evidence for altered zinc metabolism,
including elevated CSF levels of 80% and decreased temporal lobe levels, has
been found.22 An abnormality in the distribution of zinc may cause these
high extracellular and low intracellular zinc concentrations in the AD brain.
P-sheet structures are frequently found associated with zinc-binding
proteins and CD studies have shown that fibril formation is associated with
the attainment of 3-sheet structure. 23 A likely binding site for metals
involves the pair of histidine residues at positions 13 and 14 of the P protein
in conjunction with carboxylate anions from surrounding amino acids.
These amino acids are known to participate in zinc-binding in several
enzymes and other proteins.24 The rat P protein variant has a His to Arg
replacement at position 13 of the 3 protein which may result in a diminished
affinity for metal ions.
Several groups have reported conflicting results regarding the affinity
of the p protein towards zinc and copper. In several of these studies, a
comparative analysis has been made between several P protein analogs, such
as the wild-type, rodent, and Dutch forms, and the effect of zinc on their
aggregation. Bush and coworkers found that the human and rat peptides
differ drastically in their aggregation response to zinc, with a 100-fold lower
[Zn 2 +] needed to promote aggregation of the human P protein than to
promote aggregation of the rat P protein. 25 In contrast, Maggio and coworkers
found no significant difference between the rat and human peptides in the
[Zn 2+] required to induce aggregation. 21
The wild-type and Dutch 1 proteins showed little difference in the
amount of radioactive zinc that they bound, suggesting that the Glu at
position 22 in the wild-type P protein is not involved.23 The study also found
that copper, present at 20 times the concentration of zinc, was able to almost
completely displace the bound radioactivity. This result suggests that while
the binding site has a greater affinity for zinc, this site may not be unique;
however, some metals, such as calcium, were not able to displace the bound
zinc. A study by Bush, however, found that even copper was not able to
effectively displace zinc from the peptide, although it was able to stabilize
dimeric forms of the p protein.25
The above contradictory data may be the result of the several varied
experimental techniques that were used to study the problem. Interestingly,
the observed binding affinity that has been widely reported is in the
physiological range of zinc concentrations in various tissues. 2 6 The
hippocampus has the highest overall zinc content of the CNS and is also an
area consistently affected by pathological deposition of the P protein in AD. 27
The cerebellum, which has extremely low concentrations of zinc, also shows
very few amyloid plaques in AD. The extent of zinc-binding to the f protein
also depends on how much of the zinc is "free" in solution, how much zinc is
bound to other proteins, and the relative affinities of these competing
proteins for the available metal ions. However, it is possible that the in vitro
metal-binding phenomenom of the P protein may have no in vivo relevance
to AD.
Peptide Analogs
The effect of salt and HFIP on the conformation of the full length 1
protein was originally studied using 31-40. However, due to the high cost of
11-40, and in order to elucidate the effect of point mutations on the structure
of the 3 amyloid protein, several model peptides were synthesized and
subsequently studied by CD. Because of the extreme insolubility of the full-
length protein, and to facilitate peptide synthesis and purification, C-
terminally truncated analogs were studied (Figure 2.2). Initially, the P1-17
fragment was analyzed. However, this peptide had little structure, even in
the presence of HFIP. Additionally, while this peptide contains the locations
for the three rodent point mutations, it does not contain any other APP
mutations associated with AD.
Figure 2.2 Full-length and truncated 3 protein peptides.
1 17 28 40
p1-40 DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV
31-28 DAEFRHDSGYEVHHQKLVFFAEDVGSNK
P1-17 DAEFRHDSGYEVHHQKL
Ultimately, the peptide comprising the first 28 amino acids of the 3
protein sequence (pl1-28) was studied. The N-terminal 28 amino acids are
derived from the extracellular APP while residues 29-42 of the 3 protein are
derived from the putative transmembrane domain. P1-28 also contains the
cz-secretase proteolytic site where the precursor is cleaved between residues 16
and 17 of the P protein sequence.28 All three of the mutations found in the
rodent sequence of the 3 protein and some of the genetic mutations are also
located in the f1-28 segment of the protein.
Three truncated peptides, each containing only one of the three amino
acid changes found in the rodent 3-protein (pl1-28 R5G, 11-28 Y10F, and 11-28
H13R), along with one truncated peptide containing two of the changes (11-28
R5G, Y10F) were synthesized (Figure 2.3). The purpose of these peptides was
to determine whether or not the amino acids substitutions resulted in a
conformation that inhibited the binding of metals to the peptides in a way
that might prevent their aggregation. Additionally, a truncated peptide
containing the Dutch mutation responsible for HCHWA-D (13-28 E22Q) was
synthesized.
Figure 2.3 Synthetic peptide analogs of the P protein.
Although the C-terminus of the 1 protein has been shown to behave
similarly to the full length protein and to produce amyloid fibrils with nearly
identical EM and X-ray diffraction patterns, it has been proposed that the N-
terminal portion of the protein may also be critical in determining the
conformational state of the protein. While the C-terminus is comprised of
mostly hydrophobic amino acid residues, the N-terminus contains a large
number of hydrophilic amino acid residues. The N-terminus contains
proposed metal-binding regions, where the metal cations could possibly bind
to the histidine residues or carboxylate containing residues such as aspartic or
glutamic acid. 22 The structural evidence obtained from pH studies also
1 5 10 13 22 28
Human DAEFRHDSGYEVHHQKLVFFAEDVGSNK
Rat -------- G-----------F---------------- ------
R5G -------- G------------------------------- ------
Y10F ----------------- F----------------------
R5G,Y1OF --------G----------F------------- ---------
H13R ------------------ R------------------------------
E22Q ------------------------------------ Q-----
suggests that the ionization state of key residues in the 01-28 region may affect
the assembly of P-strands as influenced by His-Asp/Glu salt bridges.13
Analysis of the D Protein and Peptide Analogs by Circular Dichroism
The remaining portion of this chapter describes experiments that were
designed to probe the effect of mutations in the P protein sequence on the
metal-binding properties of the peptides. Specifically, P protein analogs were
studied by CD, and differences in the conformations of the analogs in the
presence of metals were examined.
Due to the inherent problems in using fitting programs, and the lack of
data below 190 nm, the a-helical content of spectra described in this chapter
was calculated using the methods of Greenfield and Fasman 7 and of
Morrisett 8. CD in the experiments discussed in this chapter was used
primarily as a tool for quantifying changes in the a-helix content of the
polypeptide structures rather than absolute values.
While conformational changes in the presence of metals as monitored
by CD do not reveal specific binding interactions, this method is useful in
detecting differences in conformational changes that occur in peptides
differing by only one amino acid. Experiments performed in this chapter are
based on the premise that if a peptide shows little conformational change in
the presence of a metal, it must have a weaker interaction with that metal
than a peptide that shows a large conformational change. The identification
of specific metal-ligand interactions is beyond the scope of this thesis.
The peptides described above were studied in the presence of various
concentrations of salt and organic solvent in order to probe the
conformational properties of the peptides. The standard buffer used was 6.25
mM tris hydrochloride at pH 7.4. A phosphate buffer could not be used due to
the insolubility of some of the salts. The CD spectra of most of the 0 protein
analogs were consistent with a random-coil conformation when examined in
buffer alone.
However, the peptides, excluding the p1-17 peptide, showed an increase
in a-helix upon the addition of organic solvents such as TFE and HFIP. These
solvents are known to stabilize regions of a peptide that are intrinsically a-
helical rather than induce random helix formation. TFE and HFIP are weaker
proton donors than water and therefore promote intramolecular hydrogen
bonding to occur instead of intermolecular hydrogen bonding with the
solvent.9 HFIP was used for the CD studies rather than TFE because a smaller
percentage of HFIP was required to stabilize helix formation.
The full-length 0 protein and analogs were analyzed under solvent
conditions that ranged from 0% to 60% HFIP content. For several peptides,
the peptides stock solution were initially dissolved in HFIP. In these cases,
CD analysis of the peptides in a minimum of 12.5% HFIP was required. The
CD spectra of the P1-28 peptides were taken in the presence of 16% HFIP, the
minimal amount of HFIP required to observe structure.
The conformational changes in the peptides resulting from the
addition of aqueous salt solutions were also analyzed. CD spectra were taken
in the presence of 1 EgM to 1 mM of either CaC12, CuC12, or ZnC12. The peptide
and salt solutions were added to the buffer immediately prior to scanning in
order to prevent aggregation of the peptides. Changes in the conformations
of the peptides due to aggregation, which would decrease the amount of
soluble peptide analyzed and result in a smaller CD signal, were ruled out
after no insoluble material was collected by centrifugation.
The results of the conformational studies of the full-length 0 protein
and the f protein analogs are described below. The CD spectra were
interpreted using the method of Greenfield and Fasman 7 and the method of
Morrisett8 . The interpretation of results are reported as a change in the
percent a-helix rather than in absolute terms due the analytical limitations of
CD as discussed above.
Circular Dichroism Studies of 131-40
Prior to the synthesis of truncated peptide analogs, initial CD
experiments were performed using the full-length 31-40 . Preliminary CD
studies were designed to determine the effect of HFIP on secondary structure
as well as determine the concentration dependence on the conformation of
the peptide.
In 12.5% HFIP (the lowest amount of HFIP possible due to the necessity
of making the stock peptide solution in 90% HFIP), 01-40 showed little a-
helical content. However, according to the 208 nm absorption, increasing the
HFIP to just 25% resulted in a 67% increase in the percent a-helix. Little
change was noted from increasing the HFIP above 25%. A smaller increase in
a-helix of 12% is observed as calculated by the 222 nm absorbance.
Figure 2.4 10 giM 31-40 vs. % HFIP.
Table 2.1 Percent a-helix of 10 pM 01-40 vs. % HFIP.
12.5% 25% 40% 60% 80%
208 nm 20 87 86 81 81
222 nm 51 63 64 59 59
Figure 2.5 shows that there is not a strong concentration dependence
for [1-40 from 5 gM to 20 giM. There is only an 8% increase at 208 nm
absorbance and a 3% increase at 222 nm. For all subsequent CD experiments
with [1-40, the conditions were set at 10 giM [1-40 in the presence of 25%
HFIP.
Figure 2.5 j1-40 (25% HFIP) vs. concentration.
Table 2.2 Percent a-helix of 31-40 (25%
HFIP) vs. concentration.
5 gM 10 gM 20 RM
208 nm 73 87 81
222 nm 60 63 60
In order to determine the conformational changes of 31-40 that occur
over time, a single 10 gM sample of 31-40 was scanned five times. Figure 2.6
shows that there is a significant decrease in the amount of a-helix present
over five scans when it is manipulated at room temperature in buffer. Due to
this finding, 11-40 (in a 90% HFIP stock solution) and concentrated salt stocks
were added to buffer immediately prior to scanning.
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Figure 2.6 31-40 (25% HFIP) titration test.
Table 2.3 Percent a-helix of
sample scanned repeatedly.
a single 10 jiM 31-40
#1 #2 #3 #4 #5
208 nm 78 63 46 37 32
222 nm 59 51 42 37 32
The effect of divalent metal cations on the conformation of 1-40 was
also examined. CD spectra of 11-40 were taken in the presence of 1 mM
ZnC12, CaC12, and CuC12 (Figure 2.7). Very little change in secondary structure
was observed upon the addition of 1 mM CaC12. However, large changes
were observed in the presence of ZnC12 and CuC12. Table 2.4 shows a decrease
of 87% and 47% in a-helix at the 208 nm absorbance upon the addition of
Wavelength (nm)
ZnC12 or CuC12, respectively. Due to these results only the effects of the ZnC12
and CuC12 salts were studied further.
Figure 2.7 10 giM 31-40 (25% HFIP) vs. salt.
Table 2.4 Percent a-helix of 10 j•M 31-40 vs. 1 mM salt.
11-40 ZnC12 CaC12 CuC12
208 nm 87 0 89 40
222 nm 63 8 64 46
A titration of 13-40 with ZnC12 showed that there is little change in the
conformation from 100 jiM to 1 mM ZnC12 (Figure 2.8) However, as is
evident from Table 2.5, significant decreases in a-helical structure are
observed upon the addition of small amounts of ZnC12.
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Figure 2.8 10 jgM P1-40 (25% HFIP) vs. ZnC12.
Table 2.5 Percent a-helix of 10 gM p1-40 vs. ZnC12.
[ZnC12] 0 gM 1 gM 50 jiM 75 jgM 100 giM 1 mM
222 nm 87 81 51 10 0 0
208 nm 63 62 51 22 11 8
A titration with CuC12 also showed large decreases of 87% and 52% in
a-helical content at the 208 nm and 222 nm absorbances, respectively, from 0
to 500 RM CuC12 (Figure 2.9).
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Figure 2.9 10 gM 01-40 vs. CuC12.
Table 2.6 Percent a-helix of 10 gM p1-40 vs. CuC12.
0 gM 1 gM 50 pM 100 gM 250 gM 500 gM
208 nm 87 77 56 35 10 0
222 nm 63 60 49 37 22 11
Circular Dichroism Studies of 1-17
In order to study the effect of the mutations found in the rodent 0
protein on its conformation, 01-17 was initially studied. The 01-17 sequence
contains all three of the amino acid sites that are different in the rodent
analog. However, studies revealed that the peptide was too short to possess
190 200 210 220 230 240 250
Wavelength (nm)
any secondary structure other than random coil, even in the presence of TFE
(Figure 2.10).
Figure 2.10 50 gM p1-17 vs. TFE.
In Figure 2.11, the CD spectra indicate that p1-17 has little or no cc-helix
or P-sheet, even at a concentration of 300 jgM.
performed using analogs of 31-28.
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All subsequent studies were
Figure 2.11 Concentration dependence of f1-17.
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Circular Dichroism Studies of B1-28 Analogs
/31-28 Results
Peptides comprising the first 28 amino acids of the human 01-40
variant as well as the rodent f1-40 variant were synthesized and studied. As
was the case with the full-length f protein, incubation of the peptide in buffer
can result in significant changes in secondary structure. There was a 37%
decrease in a-helical content at the 208 nm absorption when the peptide was
incubated overnight (Figure 2.12). Therefore, as with the CD analysis of P1-40,
all CD spectra of the 01-28 analogs were taken immediately after the addition
of the peptide solution to the buffer.
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Figure 2.12 20 tM human 31-28 incubated overnight.
Table 2.7 Percent (a-helix of 20 tM
31-28 incubated overnight.
t=0 hr t=24 hr
208 nm 47 10
222 nm 42 21
Conformational changes resulting from increasing the amount of HFIP
were also examined. Additionally, the effects of metal cations on the
secondary structure of the peptides were determined. CD spectra of the
peptides were taken in the presence of ZnC12 and CuC12. Figure 2.13 shows
that there are large conformational changes in human 01-28 upon the
addition of a concentrated aqueous stock solution of ZnC12. A 44% decrease
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in a-helix occurs at 208 nm from the addition of 80 gM ZnC12. Only an
additional 3% decrease in a-helix is observed from 80 to 500 gM ZnC12. A
29% decrease in a-helix is evident at the 222 nm absorption.
Figure 2.13 20 gM p1-28 human vs. ZnC12.
Table 2.8 Percent a-helix of 20 pM p1-28 vs. ZnCl2.
0 gM 20 gM 40 gM 60 gM 80 gM 500 gM
208 nm 47 43 27 18 3 0
222 nm 42 45 36 35 24 13
The addition of 80 gM CuC12 caused dramatic changes in the secondary
structure of human 31-28 (Figure 2.14). A 51% and 28% decrease in a-helix
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content at the 208 nm and 222 nm absorptions, respectively, were observed
upon the addition of the CuCl2 (Table 2.9).
Figure 2.14 20 gM f1-28 (16% HFIP) vs. CuC12.
Table 2.9 Percent a-helix of 20
gM 31-28 vs. CuC12.
0 gM 80 gM
208 nm 51 0
222 nm 43 15
fl1-28 Rat Results
CD studies of 11-28 Rat, which were done in parallel with 11-28
Human, were performed in order to determine the best concentration for the
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experiments. Although the 5 gM, 10 gM, and 20 gM concentrations seemed
to have a similar conformation (Figure 2.15), experiments were performed at
20 gM peptide.
Figure 2.15 Concentration dependence of p1-28 Rat.
Table 2.10 Percent a-helix of 20 gM
P1-28 Rat vs. concentration.
5 gM 10 gM 20 gM
208 nm 56 53 53
222 nm 48 46 45
While small conformational changes in P1-28 Rat occur upon the
addition of ZnC12 (Figure 2.16), the changes are much smaller than those seen
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for p1-28 human. A 15% and 1% decrease in a-helical content are observed at
the 208 nm and 222 nm absorbances, respectively, for 1-28 Rat in the
presence of 500 jgM ZnC12 (Table 2.11), while a 47% decrease in a-helix is
observed at the 208 nm absorbance for f1-28 human.
Figure 2.16 20 jtM 31-28 Rat (16% HFIP) vs. ZnC12.
Table 2.11 Percent a-helix of 20 pM
31-28 Rat vs. ZnC12.
0 tM 80 gM 500 pM
208 nm 30 9 15
222 nm 36 39 35
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The addition of 80 gM CuC12 results in a 17% and 11% decrease in a-
helical content at the 208 nm and 222 nm absorbances (Table 2.12),
respectively, but as was the case with the addition of ZnC12, the changes are
much smaller than the 51% decrease in a-helix observed for 01-28 human.
Figure 2.17 20 gM 31-28 Rat (16% HFIP) vs. CuC12.
Table 2.12 Percent a-helix of
20 gM 031-28 Rat vs. CuC12.
0 gM 80 gM
208 nm 30 13
222 nm 36 25
80 gM
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/31-28 YIOF Results
Large conformational changes are evident in Figure 2.18 which shows
01-28 Y10F in the presence of ZnC12. A 32% decrease in the percent a-helix is
observed at the 208 nm absorbance after the addition of 80 gM ZnC12 and only
an additional 1% decrease occurs from 80 CgM to 500 gM ZnC12. This decrease
in a-helix is similar to the 47% decrease in a-helix observed with P1-28
human in the presence of 500 gM ZnC12.
Figure 2.18 20 jgM 31-28 Y10F (16% HFIP) vs. ZnC12.
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Table 2.13
31-28 Y10F
Percent u-helix of 20 gM
vs. ZnC12.
0 lM 80 lM 500 ýM
208 nm 33 1 0
222 nm 40 27 23
In the presence of 80 .tM CuC12, there was a 33% and 23% decrease in a-
helix at the 208 nm and 222 nm absorbances, respectively (Table 2.14). Again,
these decreases are consistent with those seen with 11-28 human after the
addition of 80 iM CuC12.
Figure 2.19 20 gM 31-28 Y10F vs. CuC12.
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Table 2.14 Percent a-helix of
20 giM 01-28 Y10F vs. CuC12.
0 IM 80 gM
208 nm 33 0
222 nm 40 17
fil-28 R5G Results
The J31-28 R5G analog shows very large conformational changes in the
presence of ZnC12 (Figure 2.20). There is a 45% decrease in a-helical content at
the 208 nm absorption after the addition of 80 gM ZnC12 (Table 2.15). This is
almost identical to the 44% decrease in the percent a-helix observed upon the
addition of 80 jgM ZnC12 to 31-28 human.
Figure 2.20 20 gM p1-28 R5G (16% HFIP) vs. ZnC12.
Table 2.15 Percent a-helix of
20 gM f1-28 R5G vs. ZnC12.
0 gM 80 gM
208 nm 47 2
222 nm 48 34
fl1-28 H13R Results
Figure 2.21 indicates that the 01-28 H13R analog shows the smallest
conformational change of the three single mutation peptides upon addition
of ZnC12. No conformational change is observed at the 222 nm absorption
even after the addition of 500 gM ZnC12. The 208 nm absorption, however,
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does show a 17% and 27% decrease in a-helix in the presence of 80 gIM and
500 gM ZnC12, respectively (Table 2.16).
Figure 2.21 20 gM r1-28 H13R (16% HFIP) vs. ZnC12.
Table 2.16 Percent a-helix of 20 gM
1l-28 H13R vs. ZnC12.
0 gM 80 gM 500 gM
208 nm 49 32 22
222 nm 41 43 42
01-28 H13R shows much larger conformational changes in the presence
of 80 gM CuC12 than 500 gM ZnC12 (Figure 2.22). There is a 36% and 16%
decrease in a-helix at the 208 nm and 222 nm, respectively (Table 2.17).
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Figure 2.22 20 pM 31-28 H13R (16% HFIP) vs. CuC12.
Table 2.17 Percent oa-helix of
20 iM 31-28 H13R vs. CuC12.
208 nm
222 nm
0 gM
49
41
80 gM
13
25
The conformational changes observed in the initial studies of 31-28
R5G, Y10F in the presence of ZnC12 are shown in Figure 2.23, and are much
different than those seen with the other truncated peptides. There is a small
decrease (11%) in ea-helix at 208 nm, however, there is a 24% increase in a-
l31-28 R5G, Y1OF Results
~ II_ ___
helix at 222 nm (Table 2.18). Additional studies of this peptide are required in
order to confirm this unique conformational change in the presence of zinc.
Figure 2.23 20 jiM f31-28 R5G, Y10F (16% HFIP) vs. ZnC12.
Table 2.18 Percent a-helix
content of r31-28 R5G, Y10F vs.
ZnC12.
0 jM 80 gM
208 nm 69 58
222 nm 47 71
The conformational changes observed in Figure 2.24 that result from
the addition of 80 gIM CuC12 to 31-28 R5G, Y10F are similar to the changes
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observed in the other peptides. There is a 37% and a 31% decrease in a-helical
content at the 208 nm and 222 nm absorbances, respectively (Table 2.19).
Figure 2.24 20 jgM 1-28 R5G, Y10F (16% HFIP) vs. CuC12.
Table 2.19
S1-28 R5G,
Percent a-helix of
Y10F vs. CuC12.
0 gM 80 gM
208 nm 37 0
222 nm 40 9
fl1-28 E22Q Results
There was a 37% and an 18% decrease in the percent cc-helix of P1-28
E22Q at the 208 nm and 222 nm absorptions, respectively, from 0 to 500 gM
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ZnC12 (Table 2.20). These conformational changes are somewhat smaller that
those observed for the wild-type P1-28.
Figure 2.25 20 giM 31-28 E22Q (16% HFIP) vs. ZnC12.
Table 2.20 Percent oa-helix of 31-28
E22Q vs. ZnC12.
0•tM 80 gM 500 gM
208 nm 60 37 23
222 nm 49 53 31
Figure 2.26 shows the effect of CuC12 on 01-28 E22Q. There was a 36%
and a 19% decrease in a-helix at the 208 nm and 222 nm absorbances,
respectively, after the addition of 80 jiM CuC12 (Table 2.21).
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Figure 2.26 20 gM 31-28 E22Q (16% HFIP) vs. CuC12 .
Table 2.21 Percent c*-helix of
31-28 E22Q vs. CuC12.
0 LM 80 gM
208 nm 60 24
222 nm 49 30
Discussion
CD analysis was initially performed on the full length P protein, 11-40.
In order to determine residues critical to zinc-binding in the human and rat P
proteins, truncated peptides were synthesized. Studies with 13-17 were
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ineffective because the peptide was too small to possess any structure, even in
the presence of a helix-inducing, non-polar organic solvent such as HFIP.
Several analogs of p1-28 were therefore analyzed in order to determine ligand
interactions that were essential for zinc to bind to the peptides. The rat P-
amyloid protein differs from the human protein by three amino acid residues
(R5G, Y10F, H13R). All three substitutions are located in the N-terminal
extracellular 28-residue segment of the P protein. In addition to the human
and rat sequences, three peptides were synthesized that each contained one of
the three mutations found in the rat P protein. A fourth peptide containing
two of the mutations (R5G, Y10F) was also synthesized.
Conclusions made from the experimental results presented above are
based on the hypothesis that the larger the conformational change of the
peptide in the presence of metal, the stronger the interaction of the peptide
with that metal. A conformational change does not demonstrate
unequivocally this metal-binding interaction. However, differences between
peptides in the amount of conformational change that results from an
interaction with metal is a useful tool for examining the effect of amino acid
mutations on peptide structure. Provided that these in vitro results have in
vivo significance, the observed differences in metal-binding properties of the
1 protein variants could be important in the pathogenesis of AD.
The CD spectrum of the 1-28 analogs in buffer alone was consistent
with a random-coil conformation.7 However, the peptides showed increased
helicity upon the addition of HFIP, which is known to stabilize regions of
peptides or proteins that are intrinsically ca-helical in nature rather than
induce helix formation randomly.9
In the presence of 16% HFIP, the P protein analogs differed in the
amount of ca-helix present even in the absence of metals, which makes
subsequent comparisons between the peptides more difficult. Table 2.22
shows that according to the 208 nm absorbance, 11-28 Rat and 31-28 Y10F
initially have less a-helix than 11-28 human, 13-28 R5G, and 13-28 H13R.
Table 2.22 a-helix content of the 11-28
peptides (at 208 nm).
Peptide % a-helix
P1-28 47
1l-28 Rat 30
31-28 Y10F 33
31-28 R5G 47
31-28 H13R 49
In the presence of 80 gtM ZnC12 , a large decrease in a-helicity is
observed for the human peptide at 208 nm. The 1 protein analogs, Y10F and
R5G, which each contain only one of the rat peptide mutations also show
large decreases in helicity at 208 nm in the presence of ZnC12 . The 13-28 rat
and H13R peptides, however, show much smaller decreases in helicity in the
presence of zinc. Even after the addition of 500 tM ZnCl2 , the peptides show
only small decreases in their a-helix content (Table 2.23).
Table 2.23 Decrease in ao-helicity of the 31-28 analogs at 208
nm in the presence of either 80 or 500 IiM ZnC12.
Peptide 80 giM Zinc 500 giM Zinc
p1-28 44 47
p1-28 Rat 21 15
31-28 Y10F 32 33
P1-28 R5G 45 NA
P1-28 H13R 17 0
These results indicate that the histidine at position 13 in the P protein
may be important for its interaction with the zinc cations, which may be
stabilizing f-structure in the peptide. The replacement of this histidine with
an arginine in 1-28 H13R diminishes the effect of the metal on the
conformation of the peptide, causing it to behave in a similar manner to the
p1-28 rat peptide. Conversely, the R5G and Y10F mutations do not appear to
have a dramatic effect on the interaction of the P protein with zinc.
Therefore, only one amino acid change (the H13R mutation) of the three
changes found in the rat P protein appears to be responsible for the decreased
interaction of that protein with metals.
Histidine residues are known to play an important role in other zinc
binding proteins such as zinc fingers which regulate transcription. These
proteins contain several 30 residue repeats, each of which contains two
cysteine and two histidine residues that are ligands to a zinc atom. Other
zinc-binding proteins such as carboxypeptidases have two histidine residues
and one glutamic acid residue that are ligands to a zinc atom. Therefore, it is
not surprising that the H13R mutation may be essential for the P protein to
bind strongly to zinc.
A peptide corresponding to the P protein variant associated with
Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch Type
(HCHWA-D) was synthesized. The P protein (pl1-39) involved in this disease
contains a mutation at residue 22 in which a glutamic acid residue is replaced
by a glutamine. An analog of 31-28 with this mutation (31-28 E22Q) was
synthesized in addition to the peptides previously reported.
Large conformational changes are observed after the addition of 80 giM
CuC12. Previous studies involving the interaction of the 0 protein with
copper have presented conflicting data. One study found that copper was not
able to displace radioactive zinc form the P protein,25 while another showed
that copper did displace the bound radioactivity. 23 The latter study concluded
that the metal-binding site on the P protein may be somewhat non-specific.
Results presented herein also indicate that the 3 protein analogs may have
binding sites that are not unique to only one metal.
A smaller conformational change is observed in the 11-28 E22Q peptide
than the wild-type variant in the presence of 80 giM ZnCl 2, but the two
peptides behave more similarly after the addition of 500 gM ZnC12 (Table
2.24). This suggests that either 11-28 E22Q has a different binding contant
than 11-28 human, or that the mutation is not important to the conformation
of the protein. Results of another study showed little difference between the
wild-type and HCHWA-D P proteins in their ability to bind 65Zn 2 +.23
However, differences in the conformation of the two peptides in the presence
of metal that can not be detected by CD, but that are important in vivo, may
exist and could be critical to the metal-binding properties or proteolytic
processing of the protein.
Table 2.24 Decreases in the percent ac-helicity of 01-28 E22Q
at 208 nm in the presence of either 80 or 500 pgM ZnCl 2.
Peptide 80 gM ZnC12 500 9M ZnC12
01-28 44 47
P1-28 E22Q 23 37
Experimental
Materials
The Wang resin (Substitution 0.6 mmol/g) and Pam Resin
(Substitution 0.4 mmol/g) were purchased from Novabiochem. Boc-amino
acids and Fmoc-amino acids were obtained from Advanced ChemTech. BOP
reagent was obtained from Richelieu Biotechnologies. DIEA was purchased
from Aldrich Chemical and distilled from ninhydrin under reduced pressure.
Millex-FG 0.22 gim filters were obtained from Millipore.
Peptide Synthesis (Fmoc)
Fmoc-protected peptides were synthesized manually on the Wang
resin using commercially available Fmoc-amino acids. The side chains of
histidine and glutamine were protected by trityl groups. The side chains of
serine, aspartic acid, glutamic acid, and tyrosine were protected as the t-butyl
ethers. Lysine was protected by the Boc group and arginine was protected by
the PMC group. Amino acids were coupled to the resin with 3 equivalents of
amino acid, 3 equivalents of BOP or PyBOP, and 6 equivalents of DIEA in
DMF for 1.5 hr. The Kaiser test 29 was used to monitor coupling efficiency.
Unreacted N-termini were acetylated with acetic anhydride and DIEA (10
equivalents each in dichloromethane) for 30 minutes. The Fmoc protecting
groups were removed with 50% piperdine/DMF for 25 min. The resin-bound
peptides were cleaved and deprotected with the following for 2.5 hr at 250C:
82.5% TFA, 5% H20, 5% phenol, 2.5% EDT, and 5% thioanisole. The resin was
filtered and washed with 4 mL neat TFA. The filtrate was concentrated and
added to cold diethyl ether. The precipitated peptide was pelleted by
centrifugation, washed with ether, and dried under vacuum.
Peptide Synthesis (Boc)
Peptides were synthesized manually by Boc chemistry on the Pam resin
using commercially available Boc-amino acids. The histidine side chains
were protected by benzyloxymethyl groups, the serine and glutamic acid side
chains were protected by benzyl groups, the aspartic acid side chains of aspartic
acid were protected by either t-butyl or cyclohexyl groups, the lysine side
chains protected by 2-chlorobenzyloxy carbonyl groups, the tyrosine side
chains were protected by 2,6-dichlorobenzyl groups, arginine side chains were
protected by mesitylenesulfonyl groups. Amino acids were coupled to the
resin with 3 equivalents of amino acid, 3 equivalents of BOP, and 5.3
equivalents of DIEA in DMF for 1.5 hours. The Kaiser test29 was used to
monitor coupling efficiency. Unreacted N-termini were acylated with acetic
anhydride and DIEA (10 equivalents of each in dichloromethane) for 30
minutes. The Boc protecting groups were removed with 25%
TFA/dichloromethane for 30 minutes.
Deprotection and cleavage of Boc-peptides were achieved by the
addition of DMS (13 ml) and p-cresol (4.0 ml) to the resin-bound peptide (1.63
g) in a Teflon tube. While under vacuum, anhydrous HF (5 ml) was added
into the chamber and the solution was stirred for 2 hours at 0°C. The HF and
DMS were then removed by distillation. Additional anhydrous HF (20 ml)
was then added to the chamber and the mixture was stirred for 1 hour at 0OC.
The HF was then removed and the contents of the chamber were placed
under vacuum overnight and then diluted with neat TFA (3 ml). The
peptide was precipitated with ice-cold anhydrous ether. The precipitated
peptide was collected by centrifugation, washed with additional ether, and
dried under vacuum overnight.
Synthesis of 3 Protein Analogs
Synthesis of /1-28 Human
Synthesized by Santosh Nandan using standard Fmoc chemistry on the
Wang resin. Amino Acid Analysis: D/N 3.8 (4), E/Q 4.0 (4), S 1.8 (2), G 2.1 (2),
H 2.5 (3), R 0.9 (1), A 2.0 (2), Y 0.9 (1), V 2.5 (3), L 1.0 (1), F 2.7 (3), K 2.0 (2).
PDMS: 3265.9 (M+H)+ and 1633.8 (M+2H)+ (calc. 3262.9).
Synthesis of f1-28 Rat
Synthesized using Boc chemistry on the Pam resin and deprotected as
described above. Amino Acid Analysis: D/N 3.6 (4), E/Q 3.8 (4), S 1.8 (2), G 3.0
(3), H 1.5 (2), R 0.8 (1), A 2.0 (2), V 3.1 (3), L 1.2 (1), F 3.5 (4), K 2.2 (2). RPHPLC:
C4 semi-prep: 80/20 H20/CH3CN (0.1% TFA) 15 mL/min. VR = 165 mL. C4
analytical: 60/40 H20/CH3CN (0.1% TFA) 2 mL/min. VR = 24 mL. PDMS:
3165.6 (M+H)+ (calc. 3166).
Synthesis of /1-28 R5G
Synthesized using standard Fmoc chemistry on the Wang resin as
described above. Peptide was purified using a C4 analytical column. Amino
Acid Analysis: D/N 3.8 (4), E/Q 3.9 (4), S 1.6 (2), G 3.0 (3), H 2.7 (3), A 2.0 (2), Y
0.9 (1), V 2.9 (3), L 1.0 (1), F 3.0 (3), K 2.1 (2). RHPLC: C4 analytical (prep): 80/20
H 20/CH3CN (0.1% TFA) 2 mL/min. VR = 10 mL. PDMS: 3160.3 (M+H)+ and
1582.9 (M+H)+ (calc. 3163.8).
Synthesis of /1-28 Y1OF
Synthesized using standard Fmoc chemistry on the Wang resin as
described above. Peptide was purified using a C4 analytical column. Amino
Acid Analysis: D/N 3.8 (4), E/Q 3.9 (4), S 1.6 (2), G 2.0 (2), H 2.6 (3), R 0.9 (1), A
2.0 (2), V 2.8 (3), L 1.0 (1), F 3.7 (4), K 2.0 (2). RHPLC: C4 analytical (prep): 80/20
H 20/CH3CN (0.1% TFA) 2 mL/min. VR = 15 mL. PDMS: 3246.6 (M+H)+
and 1624.7 (M+2H)+ (calc. 3246.9).
Synthesis of /1-28 R5G, YIOF
Synthesized using standard Fmoc chemistry on the Wang resin as
described above. Amino Acid Analysis: D/N 3.9 (4), E/Q 3.9 (4), S 1.8 (2), G 2.9
(3), H 2.6 (3), A 2.0 (2), V 2.7 (3), L 1.0 (1), F 3.6 (4), K 1.6 (2). RHPLC: C4 semi-
prep: 75/25 H20/CH3CN (0.1% TFA) 20 mL/min. VR = 160 mL. C4 analytical:
80/20 H 20/CH3CN (0.1% TFA) 2 mL/min. VR = 16 mL. PDMS: 3151.3
(M+H)+ (calc. 3147).
Synthesis of 31-28 H13R
Synthesized by Santosh Nandan using standard Fmoc chemistry on the
Wang resin as described above. Amino Acid Analysis: D/N 4.3 (4), E/Q 4.0
(4), S 1.8 (2), G 2.0 (2), H 1.7 (2), R 1.5 (2), A 2.0 (2), Y 0.8 (1), V 2.8 (3), L 1.1 (1), F
3.0 (3), K 2.4 (2).
Synthesis of 31-28 E22Q
Synthesized by Santosh Nandan using standard Fmoc chemistry on the
Wang resin as described above. Amino Acid Analysis: Amino Acid Analysis:
D/N 4.1 (4), E/Q 4.0 (4), S 1.7 (2), G 1.9 (2), H 2.7 (3), R 0.9 (1), A 2.0 (2), Y 0.9 (1),
V 2.9 (3), L 1.1 (1), F 3.1 (3), K 2.4 (2).
Purification and Characterization of Peptides
The crude peptides were dissolved in DMSO and purified by reverse-
phase HPLC under isocratic conditions on a C4 semi-preparative column
(YMC, 2.0 X 25 cm) with water (0.1% TFA) and acetonitrile (0.1% TFA) as
eluents. Peptide fractions were combined, concentrated, and lyophilized to
yield a fluffy powder. The purity of the peptides was confirmed by reverse-
phase HPLC under isocratic conditions on a C4 analytical column (Waters,
0.39 X 30 cm). Purified peptides were analyzed by both quantitative amino
acid analysis (MIT Biopolymers Lab) and plasma desorption mass
spectrometry (PDMS). All peptides showed excellent agreement between the
predicted and observed amino acid content and molecular weight.
Circular Dichroism Spectroscopy
CD spectra were obtained with an AVIV spectrapolarimeter in the
laboratory of Dr. Daniel Kemp, Department of Chemistry, MIT. Stock
solutions of each peptide were prepared in distilled, high grade
hexafluoroisopropanol (HFIP) and filtered through 0.22 gpm non-aqueous
filters (Millex). Concentrations were determined by quantitative amino acid
analysis (MIT Biopolymers Laboratory). CD samples were prepared by adding
the stock peptide solutions to 1.5 ml Eppendorf tubes containing either buffer
only (6.25 mM Tris-Cl, pH 7.4) or buffer plus 80 gM ZnC12 immediately prior
to CD analysis to give a final peptide concentration of 20 gM in 16% HFIP.
Samples were incubated at 250C for 20 min prior to analysis. Each sample was
scanned four times in a quartz cell (0.1 cm pathlength) at 0.5 nm intervals
over the wavelength range 190 to 250 nm. Solvent and cell backgrounds were
subtracted from each sample. Spectra were recorded at 250C.
Results are expressed in terms of molar ellipticity in units of
deg-cm 2/dmol. All CD spectra described above are representative of at least
three CD runs. The CD spectra were smoothed by a factor of five using Cricket
Graph in order to reduce the noise levels. The percent a-helix was
determined using both the 208 nm7 and the 222 nm8 absorptions.
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Chapter 3
Apolipoprotein E and its Relationship with
Alzheimer's Disease
Despite the key advances that have been made in the field of AD in the
past decade, the etiology of the disease has yet to be elucidated. The presence
of exogenous proteins has been suggested to play a critical role in the
pathogenesis of AD. 1 In this chapter experiments examining the aggregation
of the 3 protein and the effect of apolipoprotein E (apoE) on this process have
been performed. The nucleation-dependent polymerization of the 3 protein
has been previously described in detail by Joseph Jarrett in our laboratory.2
Although controversy exists regarding the role of apoE in AD, experiments
from our laboratory demonstrate that apoE is an in vitro inhibitor of amyloid
formation.
Amyloidosis as a Cause of Disease
Amyloidosis involves the polymerization of proteins that are
normally innocuous and soluble into amyloid fibrils as a result of diverse
biochemical conditions. The amyloid fibrils accumulate into bundles and
then into fibrous plaques, invade the extracellular spaces of organs, and
destroy normal tissue architecture and function.3 Amyloid deposition is a
characteristic of over twenty diseases (Table 3.1). The amyloid deposition may
affect only one organ or may occur in multiple organs, as is the case with
systemic amyloidosis.
Table 3.1 Precursors of human amyloidogenic proteins and the proposed
cause of amyloid formation (P, proteolysis; M, mutation; C, conformational
change).2,3
Distribution Precursor (size) Cause Amyloid Protein (size)
Systemic Immunoglobulin (23 kD) P Immunoglobulin (5-23 kD)
Systemic Apolipoprotein-SAA (12 kD) P Apolipoprotein-SAA (8 kD)
Systemic Apolipoprotein-AI (26 kD) M,P Apolipoprotein-AI (9-11 kD)
Systemic Transthyretin (14 kD) M,P,C ATTR (5-14 kD)
Systemic Gelsolin (90-93 kD) M Gelsolin (7 kD)
Pancreas Pro-IAPP (14 kD) P IAPP (4 kD)
Thyroid Calcitonin (9 kD) P Calcitonin (6 kD)
Muscular P-2-microglobulin (12 kD) C 3-2-microglobulin (12 kD)
Brain 3APP (110-135 kD) P,M P protein (4 kD)
Brain Cystatin C (13 kD) M Cystatin C (12 kD)
Brain PrP cellular (30-35 kD) C Prion (27-35 kD)
Instances of increased fibrillogenesis associated with point mutations
in amyloidogenic proteins have been reported. For example, a mutation in
cystatin C results in hereditary cerebral hemorrhage with amyloidosis of the
Icelandic type (HCHWA-I).4 Finnish amyloidosis is caused by a mutation in
the gesolin peptides.5
Although there are some exceptions, most of the amyloid associated
diseases share common features. For example, defective proteolytic
processing, high local concentrations, and the existence of structural variants
often result in the extracellular accumulation of these proteins in the form of
amyloid fibrils. Additionally, most amyloidoses are diseases of aging, with
the exception of juvenile rheumatoid arthritis and AD associated with
Down's syndrome patients.3
Mechanisms for Protein Polymerization
The common factor in all of the amyloidoses seems to be protein-
protein interactions stabilized by both the structure of the protein and the
microenvironment. The kinetics of amyloid formation by amyloidogenic
proteins have been studied in order to elucidate their mechanism of
polymerization. Aggregation of these proteins into amyloid plaques could
occur according to several different mechanisms, although all mechanisms
involving aggregation must initially involve successive bimolecular
associations. 6
The first mechanism is characterized by simple growth in which the
addition of each monomer is equally favored regardless of the size of the
aggregate. Exponential growth characterizes the second mechanism such that
the addition of each monomer to the aggregate is more favorable than the
last. The third mechanism is described by nucleation-dependent
polymerization. This mechanism is more complicated than the first two
mechanisms because there are two phases: the nucleation phase (lag time)
and the growth phase. This model assumes that nucleation is entirely rate-
limiting.
The nucleation phase is observed as a lag time prior to the aggregation
of the protein and is a result of the unfavorable initial equilibria. During the
lag time the gain in enthalpy resulting from the addition of the monomer to
the growing oligomer does not outweigh the loss of entropy of the monomer.
However, once an oligomer forms that is large enough to allow sufficient
contacts between the monomer and the oligomer to make the monomer
addition favorable , the addition of monomers becomes rapid and the growth
phase begins. This oligomer is defined as the nucleus. The only detectable
states in the aggregating solution should be monomers and oligomers that are
larger than the nucleus. Any oligomers that are smaller than the nucleus are
unstable and constitute no appreciable population. Aggregation of the
protein continues until the solubility of the protein, or equilibrium, is
reached.
The concentration dependence of the lag time (tm) is based on Equation
3.1 which predicts that tm is inversely proportional to the initial monomer
concentration (Mo) raised to the number of monomers that make up the
nucleus (n). The constant k is unique to each protein polymerization
mechanism. Due to the exponential nature of this equation, very small
differences in the monomer concentration can result in large changes in the
lag time. This concentration dependence can have a significant effect on the
in vivo formation of amyloid over time.
Equation 3.1 1/tm = k[Mol n
The mechanism of amyloid formation may be the result of a
combination of both thermodynamically- and kinetically-limited processes. 2
In tubulin polymerization, an example of a thermodynamically-limited
mechanism, growth is initially slow but can be detected during the lag time.
This indicates that tubulin polymerization occurs through a steady-state
Figure 3.1 Nucleation-dependent mechanisms for microtubule
formation: A) linear aggregation followed by loop closure, B) sheet
assembly followed by tube closure, and C) experimental data and
theoretical curves predicted by model B above.
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production of nuclei. The mechanism for tubulin nucleation is depicted in
Figure 3.1.2
An example of a kinetically-limited mechanism is the aggregation of
hemoglobin S in sickle cell anemia. The polymerization of hemoglobin S,
which is responsible for sickle cell anemia, is one of the best understood
protein self-assembly systems.7 In hemoglobin S, a mutation resulting in the
replacement of glutamic acid with valine creates a hydrophobic patch on the
molecule which causes it to aggregate into multistranded helical polymers
that subsequently aggregate into bundles.
This kinetically-limited polymerization is characterized by the
complete absence of growth during the lag time prior to aggregation. This
indicates that hemoglobin nucleation does not occur through a steady-state
production of nuclei which is observed for tubulin polymerization. The
formation of aggregate is slow because the initial rates in the mechanism are
very slow. Equilibrium is reached rapidly due to an autocatalytic mechanism
that results from heterogeneous nucleation in which prenucleus oligomers
are stabilized by pre-existing fibrils, as is depicted in Figure 3.2.2
Nucleation-Dependent Polymerization of the D Protein
Previous studies by Joseph Jarrett and Elizabeth Berger have shown
that the aggregation of the P protein is a nucleation-dependent process. 8 The
kinetic curves that are obtained appear to be described by features from the
polymerization of both tubulin and hemoglobin. Nucleus formation is
initially rate-limiting, while the growth phase is thermodynamically-limited
and reaches steady-state conditions.2 A long nucleation phase (delay time)
occurs prior to the growth phase, however a small accumulation of aggregates
Figure 3.2 Nucleation-dependent mechanisms for the aggregation of hemoglobin
S: A) slow homogeneous nucleation followed by rapid heterogeneous nucleation
on preexisting fibrils, B) typical experimental data measured by turbidity.
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can sometimes be seen during the lag time.
The addition of preformed fibrils (or seeds) to a supersaturated solution
of the p protein results in the elimination of the lag time. 2 The seed fibrils act
as a nucleus onto which peptide monomers can add. This bypasses the
unfavorable formation of the nucleus and results in immediate growth of the
amyloid fibrils. Figure 3.3 shows a general mechanism for the formation of
amyloid.
Figure 3.3 A general mechanism for nucleation-dependent formation of
amyloid fibrils. A lag time occurs due to unfavorable association equilibria
(Kn). After the formation of the nucleus, growth is rapid (Kg).
Very large differences in the solubilities of 13-39 and 11-42 have
previously been reported.9 Joseph Jarrett and Elizabeth Berger demonstrated
that these three C-terminal residues had a dramatic effect on the aggregation
of the 0 protein. 8 01-40 and 01-39 have lag times of several days while P1-42
aggregates immediately. Additionally, f1-40 and f1-39 can be seeded by P1-42.
This seeding phenomenon suggests a pathogenic role of 11-42 in AD by which
small amounts of 11-42 could promote fibril formation by shorter and more
soluble variants of the 0 protein.
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Apolipoprotein E
Apolipoprotein E (apoE) is one of the best characterized
apolipoproteins in terms of its structural and functional properties of the
approximately 14 plasma apolipoproteins described to date. Apolipoproteins
can perform one of three major roles in the body.10 First, apolipoproteins
stabilize the pseudomicellar structure of lipoprotein particles due to their
ability to bind proteins that participate in the metabolism of lipoproteins as
they circulate in plasma. Secondly, apolipoproteins can act as cofactors for
various lipid transfer proteins that participate in the metabolism of
lipoproteins as they circulate in the plasma. Lastly, two apolipoproteins,
apoB100 and apoE, can serve as ligands for cell surface lipoprotein receptors.
Receptor-mediated pathways are key components of lipoprotein metabolism
and cholesterol homeostasis. 10
Additional functions and properties have been ascribed to apoE. These
include roles in immunoregulation11, nerve regeneration 12, and lipoprotein
lipase13 . However, the discovery in 1991 that apoE was present in the amyloid
plaques found in the brains of AD victims suggested a much more interesting
function of apoE than those previously described. 14 In 1993, it was reported by
the Roses group at Duke University Medical Center that APOE4, a naturally
occurring allele of the gene encoding apoE, is a risk factor for late-onset AD.15
The polymorphic nature of apoE was established in 1982 using
isoelectric focusing and two-dimensional electrophoresis. 16,17 The three
major isoforms of apoE (apoE2, apoE3, and apoE4) are the result of three
alleles (APOE2, APOE3, and APOE4) at a single gene locus. The expression of
two of the three alleles leads to either three homozygous phenotypes, which
are apoE2/2, apoE3/3, and apoE4/4, or three heterozygous phenotypes, which
are apoE3/2, apoE3/4, and apoE4/2. The most common allele is APOE 3
and the most common phenotype is apoE3/3. ApoE3 is therefore considered
to be the parent form of the protein while apoE2 and apoE4 are variants.
ApoE2 is associated with type III hyperlipoproteinemia and is defective in
receptor binding. s8 ApoE4 displays normal binding but is associated with
elevated plasma and LDL which is consistent with increased coronary heart
disease in apoE4/4 homozygotes. 19 ApoE2 and apoE4 each differ from apoE3
by only one amino acid out of 299 (Table 3.2).
Table 3.2 Polymorphic amino acids in
the three isoforms of apoE.
112 158
apoE2 Cys Cys
apoE3 Cys Arg
apoE4 Arg Arg
The gene encoding apoE is located on chromosome 19.20 ApoE is
produced in most organs with significant quantities found in the liver, brain,
spleen, lung, and kidney. The second largest concentration (after the liver) of
apoE mRNA is found in the brain.21 ApoE is secreted by a wide variety of
cells in the brain, including astrocytes. Following neuronal injury or
degeneration, local apoE synthesis by astrocytes is dramatically increased. 22
ApoE is also the major apolipoprotein in the CSF of humans.23
Structure of apoE
ApoE was first described in 1973 as an arginine-rich component of
triglyceride-rich very low-density lipoproteins (VLDL) with a relative
molecular mass (Mr) of 34,000.24 The sequence of apoE was determined in
1982 by direct protein sequencing of 299 amino acids (Figure 3.4).2 5 Human
apoE shares a high degree of sequence conservation across several species. 26
Figure 3.4 The amino acid sequence of human apoE2. The two sites of point
mutations (112 and 158) distinguishing the three isoforms are shown in bold.
1 10 20 30 40 50 60
KVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDYLRWVQTLSEQVQEELLSSQVTQEL
70 80 90 100 110 120
RALMDETMKELKAYKSELEEQLTPVAEETRARLSKELQAAQARLGADMEDVCGRLVQYRG
130 140 150 160 170 180
EVQAMLGQSTEELRVRLASHLRKLRKRLLRDADDLQKCLAVYQAGAREGAQRGLSAIRER
190 200 210 220 230 240
LGPLVEQGRVRAATVGSLAGQPLQERAQAWGERLRARMEEMGSRTRDRLDEVKEQVAEVR
250 260 270 280 290
AKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH
Based on the Chou-Fasman algorithm for prediction of secondary
structure27, apoE is predicted to be highly helical, segregating into two ordered
N- and C-terminal domains connected by a random coil.25 The cc-helix, P-
sheet, P-turn, and random structure contributions are predicted to be 62%, 9%,
11%, and 18%, respectively (Figure 3.5).28
Figure 3.5 Predicted secondary structure of apoE, showing u(-helices,
P-sheet, and p-turns (remainder is random coil).28
ApoE remains a tetramer over a wide range of concentrations. 29
Additionally, apoE displays two transitions when denatured by guanidine
hydrochloride (GuHC1) and protein unfolding is monitored by CD. The first
occurs at 0.7 M GuHC1, where most other apolipoproteins are completely
unfolded, and the second occurs at 2.4 M GuHC1.30 These results indicate that
apoE contains two independently folded regions, one of which possesses a
very high stability that is unique among plasma apolipoproteins.
This observation is supported by evidence demonstrating that upon
exposure to limited proteolysis by five proteases, there are two protease-
resistant domains. 30 After cleavage with thrombin, a 22 kD N-terminal
domain (amino acids 1-191) and a 10 kD C-terminal domain (amino acids 216-
299) are generated. The denaturation curves of these two domains indicate
that the 22 kD domain closely approximates the highly stable domain of the
full-length apoE while the 10 kD domain approximates the less stable
domain.
Size-exclusion chromatography demonstrated that the 22 kD domain is
monomeric and the 10 kD domain is tetrameric, most likely with the
hydrophobic surfaces of the amphiphilic helices sequestered within the
interior of the bundle.29 This suggests that tetramerization of the full-length
protein is mediated by the C-terminal 10 kD domain. Both domains have
been shown to by highly helical by CD.
Crystal structures of the 22 kD domains of apoE2, apoE3, and apoE4
have been determined.31 The structures contain five helices, four of which
are arranged in an antiparallel four-helix bundle (Figure 3.6). The
hydrophobic side-chains are packed within the interior of the bundle, adding
to the stability of the structure, while the hydrophilic side chains are solvent
exposed. Due to an inability to make crystals from the 10 kD domain, there is
far less structural information for this domain.
While the 10 kD domain of apoE has been defined as the lipid-binding
portion of the full-length protein, the 22 kD portion of the molecule has also
been shown to bind phospholipids in vitro.32 The hydrophobic side-chains of
the 22 kD four-helix bundle are directed toward the interior of the bundle.
Lipid association is required for high-affinity binding to the LDL receptor and
it is proposed that the hydrophobic faces of the apolipoprotein amphipathic
helices interact with the hydrophobic acyl chains of phospholipids.
Figure 3.6 The four-helix bundle motif of the 22 kD
domain of apoE3, as determined by its crystal structure.
Function of apoE
ApoE plays an important role in plasma lipoprotein metabolism,
cholesterol homeostasis, and local lipid transport processes.28 ApoE is a
ligand for the low-density lipoprotein (LDL) receptor, and apoE enriched
lipoprotein particles also bind to the LDL-receptor-related protein (LRP).22
ApoE that is secreted by active astrocytes in the brain performs two functions.
ApoE removes the lipids released by degenerating neurons and it transports
lipids to sprouting neurons. ApoE also decreases neurite branching and
promotes neurite extension away from the neuronal cell body.22
ApoE binds to the LDL receptor and selective chemical modification
studies have demonstrated that lysyl and arginyl residues are important for
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the interaction.33 Although intact apoE forms a stable tetramer in solution,
this tetramerization does not appear to be required for lipid-binding or
binding to the LDL-receptor. 29
The lipid-binding properties of the 22 kD and 10 kD domains were
determined by their ability to form complexes with
dimyristoylphosphatidylcholine (DMPC). The results indicated that the
relative lipid-binding efficiency of the intact apoE was approximately equal to
the 10 kD domain, and that the 22 kD was less efficient.34
The 22kD domain is capable of associating with phospholipid to form
discoidal complexes, although this fragment associates poorly with native
lipoproteins. However, when recombined with phospholipid, it was
determined that the 22 kD N-terminal domain (amino acids 1-191) was active
and therefore must be the receptor-binding domain of intact apoE.32 The 10
kD C-terminal domain showed no receptor-binding ability, even in the
presence of lipid.
While the 22 kD domain appears to be the receptor-binding domain,
most evidence suggests that the 10 kD domain of apoE contains the lipid-
binding site. According to CD data, the a-helical content of apoE and the 10
kD fragment increased upon phospholipid binding.29 C-terminally truncated
mutants of apoE were studied in order to define more precisely the regions of
this domain responsible for its lipid-binding properties.35 The results
demonstrated that the deletion of residues 267-299 impairs the association of
apoE with lipoprotein particles, suggesting further that these residues in the
C-terminal domain are essential to lipid binding.
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The Connection of Apolipoprotein E with AD
ApoE was first suggested as playing a role in the pathogenesis of AD
after it was identified as an amyloid-binding protein and was localized in
senile plaques.36 The genetic localization of apoE on chromosome 19 fit in
well with previous studies that reported genetic linkages and associations
between markers on chromosome 19 and late-onset AD.37
Further genetic studies have strengthened the hypothesis that apoE is
an important risk factor in AD. The Roses group at Duke University
completed a study of apoE genes in 234 people from 42 families afflicted with
late-onset AD. By age 80, almost all the people in the study who had two
copies of the APOE4 allele developed the disease.15 Their overall risk was
more than eight times greater than that of people with no copies of the gene.
The establishment of apoE4 as a risk factor for late-onset AD was the first
major breakthrough in establishing genetic causes for the most common
form of AD. Late-onset AD is currently responsible for 75% of all cases of
AD.38
A gene dosage effect for the risk of developing AD and the age of onset
has been observed. People who have two copies of the APOE4 allele have a
much higher risk of developing AD at an earlier age than do people with no
APOE4 alleles. However, people who only have one copy of the APOE4 allele
are intermediate in both their risk for developing AD and the age of onset of
the disease (Figure 3.7).15
101
Figure 3.7 Correlation of apoE genotype with
AD risk and age of onset.15
Apo E genotype Percent Mean age
normal pop.) affected at onset
3/3 (61%) 21% 84
3/4 (22%) 48% 75
4/4 (3%) 91% 68
The genetic link between apoE and AD is controversial. It is possible
that apoE has nothing to do with the pathogenesis of AD. There could be an
AD causing gene lying close enough to the APOE locus that genetic
epidemiology confuses the two. If this were true, the APOE gene would
actually be a marker for the cause of the disease.38
Effect of apoE on Brain Morphology, Memory, and Cognition in AD
In addition to an increase in the risk of developing AD, victims of AD
who are homozygous for the APOE4 allele have an increased density of senile
plaques in their brains when compared to patients who are homozygous for
the APOE3 allele or who are APOE3/4 heterozygotes. 39 This suggests that
apoE is somehow involved in the clearance of the 03 protein because it has
been demonstrated that plaques do not appear to accumulate over the course
of AD.
Additionally, while both AD associated with apoE4 and Down's
Syndrome (DS) lead to increased amyloid deposition, they appear to do so by
different mechanisms. 40 The plaques formed in DS are larger than those
found with apoE4. In AD associated with apoE4, the plaques are similar in
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size to those formed in APOE3 homozygotes, but the number of plaques is
increased.
The larger plaques associated with DS may reflect an increase in P
protein production and, therefore, in the availability of P protein monomers
for plaque growth, while the increase in the number of plaques in APOE4
homozygotes could be the result of an increased probability of senile plaque
formation. These results suggest that the function of apoE, which includes
the binding to and the transportation of hydrophobic molecules such as
lipids, could also be part of a clearance mechanism for the P protein or 1
protein aggregates. 39
If apoE4 is less efficient than apoE3 at clearing small aggregates, this
could lead to an increased chance that an aggregate would reach a critical
threshold size, leading to an increased number of senile plaques without
affecting the size distribution.
In the time since it was determined that the APOE4 allele is a risk factor
for AD, scientists have investigated whether or not the presence of different
apoE alleles in AD affect specific cognitive functions or rates of cognitive
decline differently. Thus far, the role of apoE in predicting cognitive decline
in AD has not been unequivocally proven, however, results seem to indicate
that apoE4 may be responsible for lower cognitive performance.
One study characterized the clinical status and apoE genotype of a
group of patients over the course of five years with mild cognitive
impairment (MCI) that were not clinically diagnosed with AD, and found that
the APOE4 allele appeared to be a strong predictor of clinical progression to
AD.41 Another study based on a random sample of elderly subjects with no
signs of dementia monitored memory over 3.5 years and showed that subjects
with APOE2/2 and APOE2/3 genotypes demonstrated better learning ability
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than subjects with one or two copies of the APOE4 allele. The learning ability
of these people declined much more rapidly over time.42
Another study that administered cognitive tests over a five-year period
to probable AD patients found that the rate of cognitive decline did not vary
significantly across apoE genotypes.43 However, cognitive testing was
performed at a more advanced stage of AD. This indicates that apoE4 may
affect the pathogenesis of AD only in the initial pre-symptomatic stages of the
disease. After the clinical diagnosis of probable AD, the disease may progress
identically, regardless of the apoE genotype.
Proposed Role of apoE in AD
There are presently two hypotheses that could explain the role of apoE
in AD. The first involves the neurofibrillary tangles and microtubule-
associated protein, tau. The second, and more widely supported, involves the
amyloid-cascade hypothesis.
Additionally, the effect of apoE4 on amyloid formation in AD can also
be described by two scenarios. The first suggests that apoE4 acts as a
"pathological chaperone" and promotes the transformation of j protein
monomers into an insoluble aggregate, thus facilitating plaque formation.44
The second scenario suggests that all forms of apoE actually inhibit the
formation of amyloid, but apoE4 is actually a less efficient inhibitor than
apoE3 and apoE2.45
The latter scenario involves the premise that different protein
isoforms expressed from polymorphic alleles may have slightly altered
functions with cumulative effects as people age. The relationship between
apoE polymorphisms and AD was less important when people did not live
more than 70 years and when AD was a less prevalent disease. Presently,
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several groups have shown the inhibitory effect of apoE on P protein fibril
formation, as well as the ability of apoE to attenuate the neurotoxicity of the P
protein.45-48
ApoE-Deficient Mice as a Model for AD
Depending on whether apoE4 is an inhibitor or a promoter of amyloid
formation, there are two types of genetically modified animal models that can
be studied. If apoE4 acts as a "pathological chaperone",44 then a mouse over-
expressing apoE4 might be useful in promoting the formation of amyloid
plaques in vivo. However, if apoE4 is actually an inhibitor of amyloid
formation (albeit less efficient inhibitor than apoE3), then amyloid formation
in apoE knockout mice that also overexpress APP should be extremely useful
because the ability of the animal to suppress amyloid formation should be
greatly reduced.
The density of hippocampal synapses of apoE-deficient mice is reduced
and they have a diminished regenerative capacity following hippocampal
lesions. Studies have also revealed loss of forebrain cholinergic neurons and
a preferential decrease in working memory, which are early and prominent
features of AD, suggesting that the mouse model may replicate pathogenic
processes in AD.49
One problem that is encountered when studying apoE-deficient mice is
that serum levels of cholesterol are five to six times normal in the apoE-
deficient mice. This abnormal lipoprotein phenotype in apoE knockout mice
makes the study of AD in these animals more difficult because the animals
sometimes die prematurely of aneurysms.50
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Results from In Vitro Studies of apoE and the D Protein
As mentioned above, the possession of the APOE4 allele has been
implicated as a risk factor for late-onset AD. Some have speculated that apoE4
may accelerate amyloid formation because apoE has been colocalized in the
senile plaques found in the brains of AD victimsI and appears to bind to the 0
protein in vitro.3 6 However, this hypothesis has not been experimentally
tested.
The formation of amyloid by the 0 protein is a nucleation-dependent
process and is rate-limited by the formation of the nucleus.8 ,51 The circulating
variant, 31-40, nucleates slowly relative to the C-terminally extended
variants, 11-42 and p1-43.8 Endogenous proteins such as apoE could either
promote amyloid formation by stabilizing prenucleus oligomers or seeding
growth. Alternatively, apoE could interfere with the aggregation by either
inhibiting nucleus formation or by inhibiting growth of the nucleus. Our
laboratory has found that apoE4 is a less effective inhibitor of amyloid
formation than apoE3.
ApoE is an Inhibitor of Amyloid Formation
In vitro amyloid formation by P31-40, as measured by turbidity,
demonstrated a protracted lag time in the absence of agitation. After
approximately ten days at a concentration of 40 gM, the growth of amyloid
fibrils occurred. The addition of apoE3 or apoE4 to a supersaturated solution
of the p protein in a 1:100 molar ratio of apoE:31-40 ([apoE] = 40 nM)
prolonged the lag time significantly. The lag time was extended to more than
20 days upon the addition of apoE (Figure 3.8). However, the addition of
106
insulin, bovine serum albumin, and c-crystallin at ten times the
concentration (400 nM) of apoE had no effect on the observed lag time.
Figure 3.8
proteins (40
The aggregation of p1-40 (40 gM) in the presence of exogenous
nM) in the absence of agitation.
Prenucleus oligomers are rapidly populated for 01-42 at 40 RM causing
the peptide to nucleate faster than 01-40.8 Experiments that tested the ability
of apoE to inhibit the aggregation of 31-42 were not successful because
amyloid formation occurs much more rapidly and does not exhibit a lag time
at 40 jgM (Figure 3.9). Our assay did not allow observation of the aggregation
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of p1-42 at a concentration closer to its solubility where a lag time would be
expected to occur.
Figure 3.9 Aggregation of 40 M 131-42 in the presence of apoE3 and apoE4
(400 nM).
Additional kinetic studies of amyloid formation by 11-40 were done
under stirred conditions which increased the nucleation rate significantly,
most likely by promoting secondary nucleation events. As in the unstirred
assay, an increase in the lag time was observed in the presence of a 1:100
molar ratio of either apoE3 or apoE4 to 11-40 where the apoE concentration
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was 800 nM and the P1-40 concentration was 80 jiM. The results
demonstrated that apoE4 is an equipotent or less potent inhibitor than apoE3
of amyloid formation by the 3 protein. The lag time for 31-40 was 143 ± 10
minutes; however, when 1% apoE3 was added to a supersaturated solution
prior to aggregation the lag time was extended to 258 + 12 minutes. The lag
time in the presence of 1% apoE4 was 210 ± 53 minutes (Table 3.3). A typical
representative stirred aggregation experiment showing the effect of apoE on
fibril formation is depicted in Figure 3.10.
Table 3.3 Lag times for 01-40 alone and in the
presence of 1% apoE3 and apoE4.
Lag Time (min)
(31-40 143 + 10
+ apoE4 210 + 53
+ apoE3 258 + 12
Because of the extreme sensitivity of nucleation to protein
concentration, vibrations, trace impurities, and stirring rate52, the lag time is
extremely difficult to measure more accurately.51 Consequently, the error in
our measurement of nucleation time for apoE4 was approximately equal to
the difference between apoE3 and apoE4. An additional complication results
from differences in nucleation time between commercial lots of 31-40
(Bachem), possibly due to the presence of undetectable impurities.5 3
Therefore, each experiment was done with a single (1-40 lot and only
qualitative comparisons were made between experiments done with different
lots.
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Figure 3.10 Inhibition of the aggregation of 80 RM 01-40 by 1% apoE under
stirred conditions.
ApoE Does Not Inhibit the Seeding of Amyloid Fibrils
The insignificant effect of apoE on amyloid growth rate and final
solubility in the kinetic assays above suggest that apoE does not interfere with
the post-nucleation aggregation process. Consistent with that postulate, the
presence of 1% apoE3 or apoE4 had no effect on the seeding of amyloid
formation by the addition of P1-40 fibrils added to a supersaturated solution
(Figure 3.11).
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Figure 3.11 The seeding of amyloid formation with 5% preformed amyloid
fibrils in the presence of 1% apoE3.
ApoE Does Not Effect the Structure or Solubility of f31-40
Experiments were performed to determine the solubility of 31-40 alone
and in the presence of apoE3 and apoE4. Supersaturated solutions of
radioiodinated P1-40, with and without 1% apoE3 or apoE4, were allowed to
aggregate under stirred conditions for several days. The amount of peptide
remaining in solution after three days, or its solubility, was measured by
counting the radioactivity. At concentrations sufficient to significantly delay
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nucleation, neither apoE3 nor apoE4 had a measurable effect on the solubility
of 01-40, which was determined to be 33 + 4 pM.
No structural differences were observed for amyloid fibrils formed by
01-40 alone or in the presence of apoE3 or apoE4 as demonstrated by FTIR
microscopy (Figure 3.12).
Additionally, amyloid fibrils formed in the presence of inhibitory
concentrations of apoE3 and apoE4 were indistinguishable from those formed
in their absence, with regard to their morphology as seen by electron
microscopy (Figure 3.13).
Inhibition of Amyloid Formation by the ApoE3 Dimer
Analysis of apoE3 and apoE4 by SDS gel electrophoresis under non-
reducing conditions indicated that apoE3 contained a small amount of dimer
(10-30%) under the conditions of the kinetic aggregation assays above (Figure
3.14). This has biological significance as the plasma dimer levels for APOE3
homozygotes average approximately 27% of their total apoE3. 54 This may
help to explain the more efficient amyloid suppression in APOE 3
homozygotes. The wide range in reported dimer levels (12-37%) suggests that
factors that alter the apoE3 monomer/dimer ratio may also be important in
the pathogenesis of AD. Conversely, apoE4, which does not contain a cysteine
at position 112 as apoE3 does, is unable to form a disulfide dimer.
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Figure 3.12 Infrared spectra of amyloid fibrils formed by 01-40 alone (A), in
the presence of apoE3 (B), and in the presence of apoE4 (C).
Wavenumber (cm-1)
Figure 3.13 Electron micrographs of amyloid fibrils formed by J1-40 alone (A),
in the presence of apoE3 (B), and in the presence of apoE4 (C). (Bars = 1000 A)
(See next page)
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Figure 3.14 SDS-PAGE of the full-length apoE isoforms under non-reducing
conditions (lanes 1, 3, 5, and 7) and reducing conditions (lanes 2, 4, 6, and 8)
Lanes 1 and 2 are apoE2; lanes 3 and 4 are apoE3; lanes 5 and 6 are the apoE3
dimer; and lanes 7 and 8 are apoE4.
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In order to test the possibility that dimerization was responsible for the
slight difference in the inhibitory activities of the two variants, the apoE3
covalent dimer was tested and the results are shown in Figure 3.15. The
apoE3 dimer at 400 nM, or 0.5% of a molar equivalent based on an 80 jiM
concentration of P1-40, showed a lag time of 605 + 50 minutes which was
much longer than the 224 + 100 minutes for apoE4 at twice the concentration.
The unusual shape of the inhibited aggregation curves (i.e. slight increase in
turbidity before rapid growth begins) suggests that the aggregation mechanism
may be altered.
Figure 3.15 Inhibitory effects of 1% apoE4 and 0.5% apoE3 disulfide dimer on
the aggregation of 80 M P1-40.
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Binding Studies of the fl protein with apoE
Previous studies have shown that apoE in cerebrospinal fluid binds
with high avidity to immobilized 3 protein.36 Additionally, an SDS-stable
interaction between the P protein and apoE has been described.55 In order to
test these results, the experiments were repeated in our laboratory following
the procedures given in these studies. 31-40 was incubated alone and in the
presence of apoE3, apoE4, and the apoE3 dimer. The samples were then run
on a denaturing, non-reducing gel (Figure 3.16). After repeating the
experiments several times, a band corresponding to a P protein-apoE complex
was still not detected.
Discussion
The studies presented herein demonstrate that in vitro nucleation of
amyloid formation by p1-40 is inhibited by concentrations of apoE3 and apoE4
which are low in the relative (0.1% of a molar equivalent compared to P1-40)
and absolute (40 nM) senses. ApoE is known to be produced in the brain and
a concentration of 100 nM has been measured in human cerebrospinal fluid.56
This concentration of apoE is sufficient to delay the nucleation of amyloid in
a physiologically significant way. The stoichiometry of inhibition of
nucleation by apoE3 and apoE4 suggests that apoE binds to a prenucleus
oligomeric intermediate (Figure 3.17) and prevents its elaboration, as opposed
to binding to monomeric 01-40. The fact that seeding of amyloid formation is
not prevented by apoE3 or apoE4 is consistent with that scenario.
Furthermore, 1% inhibitory concentrations of apoE do not appear to effect the
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Figure 3.16 SDS-PAGE (non-reducing conditions) of the 1 protein incubated
with apoE3, apoE4, and the apoE3 dimer for 1.25 hours. Lanes 1, 2, 4, 6, and 8
contain 01-40; lanes 2 and 3 contain apoE3; lanes 4 and 5 contain apoE4; lanes
6 and 7 contain apoE3 dimer; and lanes 8 and 9 contain apoE2.
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growth, stability, or structure of 31-40 amyloid fibrils. Thus, apoE most likely
does not interact strongly with the amyloid nucleus or the subsequent
intermediates.
Figure 3.17 A general mechanism for nucleation-dependent amyloid fibril
formation, including a working hypothesis for the effect of apoE.
The precision of the assay for amyloid formation utilized herein was
insufficient to distinguish the inhibitory activities of apoE3 and apoE4.
However, the apoE3 disulfide dimer, which was present at low levels in the
apoE3 sample, was a significantly more efficient nucleation inhibitor than
apoE4. This effect may derive from the entropic benefit of tethering two P
oligomer binding domains.
The correlation of the apoE4 allele with an earlier age of AD onset15 and
an increased amount of amyloid at the time of death5 7 has stimulated rampant
speculation concerning the underlying molecular mechanism. It has been
proposed that apoE4 may promote amyloid formation by stabilizing the
aggregating conformation of the P protein44. However, the results presented
herein prove that both common apoE variants inhibit amyloid formation in
vitro.
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Amyloidogenesis may occur at a low rate in most individuals, due, in
part, to the suppression of amyloid nucleation by endogenous apoE.
Inefficient suppression of amyloid formation by an apoE4 homozygote could
be a contributing factor to the development of AD. The in vivo
crystallizations of calcium oxalate (from supersaturated urine5 8 ) and of
calcium phosphate (from supersaturated saliva59) are also suppressed by
endogenous inhibitor proteins. The apoE3 dimer is clearly a more efficient
nucleation inhibitor than apoE4, which cannot dimerize. In addition, the
plasma apoE4 concentration of an apoE4 homozygote is ca. 40% lower than the
plasma total apoE3 concentration in an apoE3 homozygote (ca. 1.5 mM).60 The
analogous measurement of CSF or brain tissue has not been reported, but if a
comparable concentration difference exists in the brain it could partly or fully
explain the compromised ability of apoE4 homozygotes to suppress
amyloidogenesis. Finally, the correlation between apoE genotype and AD risk
may also involve events other than amyloidogenesis. 61
The findings reported herein have significant practical implications.
Transgenic apoE knockout mice in which APP is overexpressed could be
excellent models for AD amyloidogenesis, since their natural amyloid
suppression system is compromised. It has been observed that low
concentrations of apoE attenuate the neurotoxicity of the 3 protein.48 This
effect may be due to inhibition of amyloid nucleation by apoE, an activity
which may have therapeutic benefit. Prenucleus oligomers represent the
most efficient target for endogenous amyloid inhibitors since they are sparsely
populated during the aggregation process5 1 and the inhibitor protein need
only be expressed at trace levels. Synthetic, nonpeptide inhibitors could be
designed to follow Nature's strategy by "poisoning" the crystallization of
amyloid. 53
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Experimental
Materials
The 0 protein isoform p1-40 was purchased from Bachem. ApoE
proteins were obtained from Dr. Karl Weisgraber at the Gladstone Institute
(UCSF). ApoE3 and apoE4 were purified as detailed in the literature.62 The
apoE3 dimer was isolated as reported in the literature.54 The molecular
weights of these proteins and their purity were checked by SDS-PAGE under
non-reducing conditions. The apoE3 samples also contained a significant
amount of dimer (ca. 10-30%). The a-crystallin was provided by Dr. J.
Horowitz. Insulin was obtained from Sigma and bovine serum albumin was
obtained from Pierce. The Lowry protein assay kit was obtained from Pierce.
Millex-GV 0.22 jgM filters were purchased from Millipore.
Aggregation Assay (Unstirred)
Stock solutions were prepared by dissolving P1-40 (Bachem) in DMSO at
1-1.5 mM. The peptide solution was then sonicated for 30 min and filtered
through Millex-FG 0.22 gm filters. The final 01-40 concentration was
determined by quantitative amino acid analysis. Sonication and filtration
were critical in removing any trace of undissolved seeds that may resist
solubilization. In the absence of filtration, immediate nucleation was
occasionally observed, presumably due to the undetected presence of
undissolved seeds in the DMSO solution. Aliquots of 01-40 stock (40 nmol in
ca. 40 gL DMSO) were added to aqueous buffer (1000 giL total volume, 100 mM
NaC1, 10 mM NaH 2 PO4, pH 7.4). Aggregation was measured by turbidity at 400
nm vs. a buffer blank. The peptide solutions were briefly vortexed before each
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absorbance measurement in order to evenly suspend the fibrils. For
aggregation experiments with apoE, 01-40 stock (40 nmol in DMSO) was added
to buffer containing 0.1% of a molar equivalent of apoE3 or apoE4 Absorbance
(400 nm) was measured vs. a blank containing buffer and apoE.
Aggregation Assay (Stirred)
Stock solutions were prepared as previously described for unstirred
assays. Aliquots of 01-40 stock (80 nmol in DMSO) were added to aqueous
buffer (1 mL total volume), or to buffer containing 1% of a molar equivalent of
apoE. The solutions were stirred continuously (1550 rpm) and turbidity was
measured at 400 nm. Lag times were calculated by curve-fitting the steepest
growth portion of each aggregation curve and extrapolating to zero absorption.
These values were averaged to determine the lag times and standard
deviations reported in the text.
Seeding Experiments
A peptide solution of 80 giM 01-40 was stirred for three days to produce
amyloid fibrils. The fibrils were sonicated for 20 minutes and a portion of the
fibril suspension (50 gL, 4 nmol) was added to 950 giL of an 80 gM p1-40
solution in buffer containing 1% molar equivalents of apoE (800 nM).
Aggregation was monitored by turbidity at 400 nm (vs. seed alone).
Radioassay
As a complement to the turbidity assay of insoluble amyloid, the
amount of peptide remaining in solution during the aggregation process was
measured by radioassay. Radioiodinated P1-40 (ca. 250 Ci/mmol, provided by
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Dr. Harry LeVine of Parke-Davis) was added to a 01-40 stock solution which
was prepared as indicated above (1-1.5 mM in DMSO, final specific activity =
ca. 3.5 mCi/ mmol). Aliquots of peptide stock solution (40 nmol f1-40, 30-40
piL of DMSO stock) were added to buffer (ca. 460 gL) and buffer containing 1%
of a molar equivalent of apoE3 or apoE4 (0.4 nmol). The samples were stirred
and aliquots (30 gL) were removed at various time points and filtered through
0.22 gm filters. The amount of soluble peptide present in the filtrate was
measured by scintillation counting.
Solubility Determination
Supersaturated radioiodinated peptide solutions with and without apoE
proteins were prepared as above and stirred for three days. A measured
aliquot was removed, filtered, and the radioactivity was counted.
Fourier-Transform Infrared Spectroscopy
Amyloid fibrils were prepared as indicated above and analyzed using a
NIC PLAN IR microscope (32 fold objective) with a Nicolet 510P FTIR
spectrophotometer.
Electron Microscopy
Fibrils for electron microscopy were taken from kinetic aggregation
experiments (see above). Aliquots of suspended fibrils were placed onto
carbon-coated copper grids and were allowed to sit for 1-5 minutes. These
were washed with H20, and then were negative stained with 2% uranyl
acetate. Electron micrographs (EMs) were taken on a JEOL 1200 CX electron
microscope operating at 80kV with a 60,000-fold magnification.
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SDS-Polyacrylamide Gel Electrophoresis
Polyacrylamide gels were poured according to the method of
Laemmli.63 All gels were visualized by Commassie Blue R-250. All gels were
run in a Novex mini-cell system.
Binding Studies of fil-40 with ApoE
ApoE (1 jgg) was incubated for either 15 minutes or 1 hour and 15
minutes at 370C with 01-40 (60 jgg) in phosphate-buffered saline, pH 7.4, in a
total volume of 20 gl. Incubation was terminated by the addition of 20 p1 of
2X Laemmli buffer (4% SDS with no P~-mercaptoethanol) and boiled for five
minutes. Proteins were electrophoresed on a 4-20% polyacrylamide gel and
stained with Commassie Blue R-250.
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Chapter 4
Models of the N-Terminal Domain of
Apolipoprotein E
Amyloid formation by the P protein proceeds according to a
nucleation-dependent polymerization, as was discussed in Chapter 3.1 The
APOE4 allele is associated with an earlier age of onset of the nonfamilial, late-
onset form of AD, in addition to increased P protein amyloid deposition in
the brain.2 We have found that apoE is an inhibitor of amyloid formation
and that apoE4 is actually a less efficient inhibitor than apoE3.3
Proteolysis of ApoE Yields Two Intact Domains
A 22 kD N-terminal domain comprising amino acids 1-191, and a 10 kD
C-terminal domain comprising amino acids 216-299 are produced after the
full-length apoE is subjected to proteolysis by thrombin (Figure 4.1A). The 22
kD domain contains the sites that distinguish the apoE isoforms.
Experiments in this chapter were designed to determine more precisely the
region of apoE responsible for its inhibitory activity by studying the
interaction of the 22 kD and 10 kD domains with the P protein.
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Examination of the two domains by gel electrophoresis under non-
reducing conditions demonstrated that the 22 kD apoE3 protein, which has
one cysteine residue, contained approximately 20% of a disulfide dimer while
the 10 kD protein existed only as a monomer (Figure 4.1B). The inhibitory
activity of apoE was subsequently shown to be contained in the 22 kD portion
of the protein. Several recombinant 22 kD apoE isoforms and mutants were
expressed and purified in order to isolate regions of the protein that are
critical for inhibition.
Conformational Change of ApoE Resulting from Lipid-Binding
X-ray crystallography of the 22 kD domain of apoE that is produced
from proteolysis by thrombin has demonstrated that this domain contains
five helices, representing more than 80% of the residues present. Four of
these helices are arranged in an antiparallel four-helix bundle.4 The interior
of the bundle is packed with the hydrophobic side chains of the protein and
the hydrophilic side chains are located on the exterior of the helices and are
solvent-exposed.
Studies have shown that lipid is required for the 22 kD domain to
exhibit high-affinity binding to the LDL-receptor. 5 The proposed working
hypothesis for the binding of the 22 kD domain to phospholipids suggests that
the four-helix bundle undergoes a conformational change when associated
with lipid. As a result of this conformational change, the bundle opens
without major disruption of the a-helical structure (Figure 4.2).6 The opened
structure would have a broad hydrophilic face and hydrophobic face. The
hydrophobic face could then interact with the lipid.
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Figure 4.1 (A) Proteolysis of apoE by thrombin yields two intact domains. (B)
SDS-PAGE of the 10 kD domain (lanes 1 and 2) and the 22 kD domain (lanes 3
and 4) under non-reducing conditions (lanes 1 and 3) and reducing conditions
conditions (lanes 2 and 4).
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Figure 4.2 Diagram depicting the proposed opening of the 22 kD four-helix
bundle upon lipid-binding.
This hypothesis has been reinforced by experimental data. The surface
properties of the 22 kD domain at an air-water interface, a system that has
been used extensively to model the interaction of apolipoproteins with lipid7,
was examined. The surface pressure-molecular area isotherm was
comparable to data for other apolipoproteins and in the range for a-helical
homopolypeptides that lie coplanar with the surface.8 This indicates that the
helices of the 22kD fragment also lie coplanar with the surface.
Additional data supporting this hypothesis was produced from
experiments with a mutant form of the 22 kD domain of apoE3. A threonine
to cysteine mutation at position 57 in apoE was introduced to determine the
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effect of an intramolecular disulfide bond between Cys57 and Cys112 on the
properties of the domain. 9 The disulfide bond, which bridges two of the
helices of the four-helix bundle, added to the stability of the fragment and
further protected the domain against denaturation. Additionally, the Cys57
mutant possessed a much lower affinity for lipid than the wild-type 22kD
domain. This supports the theory that the four-helix bundle must open in
order to bind lipid.
Proposed Inhibitory Mechanism of ApoE 22 kD Domain
One of the many functions performed by apoE involves the binding to
and transportation of hydrophobic molecules such as lipids, as is discussed
above. This function also suggests that apoE might play a role in binding to
other hydrophobic molecules such as the P protein. 10 According to this
mechanism, apoE may act as a clearance mechanism for the P protein or P
protein aggregates.
The four-helix bundle could open as it is believed to do when binding
lipid, however, the hydrophobic face could then bind to the 3 protein instead
of lipid. The apoE-3 protein complex could then bind to the LDL receptor
where the 3 protein would subsequently be internalized and degraded.
Additionally, the various isoforms of apoE may have different
clearance abilities (inhibitory activities). For example, if apoE4 was able to
clear nuclei or small aggregates of the P protein, but was less efficient in this
role than apoE3, this could explain why over time APOE4 homozygotes were
more at risk for developing AD. This hypothesis suggests that the rate of
amyloid deposition is a reflection of the relative rates of P protein synthesis,
aggregation, and clearance.10
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A Truncated ApoE Variant
The four-helix bundle motif that is present in the 22 kD fragment is
unusual when compared to other four-helix proteins. The lengths of the four
helices are 19 (helix 1), 28 (helix 2), 36 (helix 3), and 35 (helix 4) amino acids.
Three of these helices are much longer than the average helical length of 18
residues found in other proteins sharing this folding motif.11 Currently it has
not been determined if the elongated helical bundles in apoE are a common
structural element of other plasma apolipoproteins.
Helix 1 begins at residue 23 and extends to residue 42. Helix 1 is
connected to helix 2 by a short connecting helix, encompassing residues 44-53.
Helix 2 begins with residue 54 and extends to residue 81. The chain is
reversed with a turn defined by residues 82-86. Helix 3 extends from residues
87 to 122. The chain reverses again with a turn comprising residues 123-129
and helix 4 extends from residue 130 to 165. The receptor-binding region has
been localized to helix 4 (residues 136-150).
The crystal structure of the 22 kD domain defines only residues 23 to
165. The N-terminal fragment comprising the first 22 amino acids and the C-
terminal fragment comprising the final 34 amino acids are both random coil
in nature. It was proposed by our laboratory that truncations of the 22 kD
domain might further isolate the region responsible for the inhibitory activity
of apoE. The most obvious truncations were variants of 22 kD apoE that were
missing the N- and C-terminal random-coil fragments.
Additionally, truncations that removed helices from the four-helix
bundle would be an interesting method by which to determine whether or
not the inhibitory activity of the 22 kD domain was due to this bundle motif.
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Expression of the ApoE 22 kD Variants
The previous studies performed with the full length apoE proteins
(described in Chapter 3) used proteins that were isolated from human plasma.
The isolation of apolipoproteins from plasma is limited by the number of
people who have been apoE genotyped and who are willing to donate their
blood on a regular basis. Expression of full-length apoE in E. coli systems is
extremely difficult. Very little protein is produced by the cells, possibly
resulting from the high lipid-binding affinity of the 10 kD domain of the
protein. 12
Conveniently, the expression of the 22 kD domain is much easier than
the full-length protein. The ability to express the 22 kD domain facilitates the
examination of the interaction between apoE and the P protein by providing
an easy method to produce truncated proteins and mutants. The apoE2,
apoE3, and apoE4 22 kD isoforms were subsequently expressed in E. coli cells.
The expression system utilized was the T7 promoter-driven system
originally developed by Studier and colleagues. 13 Target genes are cloned into
a vector that contains a T7 promoter (e.g. pT7 or pET series) and the resulting
construct is transformed into E. coli lysogen BL21(DE3) which contains an
inducible T7 RNA polymerase gene. Expression is induced by the addition of
isopropyl-P-D-thiogalactopyranoside (IPTG). T7 RNA polymerase is so
selective that almost all of the cell's resources are converted to target gene
expression and the desired product can comprise more than 50% of the total
cell protein after induction. Target genes are initially cloned using hosts that
do not contain the T7 RNA polymerase gene so that they are inactive and
cannot cause plasmid instability due to the production of proteins that are
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potentially toxic to the host cell. The gene encoding for the 22 kD apoE
protein was cloned into a vector containing a T7 phage promoter (deonoted as
pT22K), which was derived from pBR322. The circular map of pT22K
showing unique restriction sites that exist within the apoE gene is shown in
Figure 4.3.
Figure 4.3 A schematic diagram illustrating the circular map of pT22K and
the unique restriction sites. The solid arrow represents the 22 kD apoE gene.
ORI is the origin of replication and Ap is the ampicillin resistance gene.
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Cell Transformation and Protein Induction
Plasmids containing the cDNA coding sequences of apoE2, apoE3, and
apoE4 were transformed into E. coli BL21(DE3) cells. After the
transformation, the colonies were checked to confirm that they contained the
apoE plasmids. The plasmid inserts were cut out of the plasmids using a
restriction digest with the enzymes BamHI and NdeI. The digested material
was then examined by DNA gel electrophoresis on a 1% agarose gel (Figure
4.4). For each plasmid, two digests were performed: 0 cuts (no enzyme), and 2
cuts (BamHI and NdeI). These experiments confirmed the presence of the
desired restriction sites in the plasmid. After the cleavage by the two
restriction enzymes, a small 590 base-pair DNA fragment was liberated.
After confirmation by a restriction digest that the cells contained the
correct plasmids, the cells were grown on a one liter scale and induced by the
addition of IPTG. Induction was monitored over time. Cell samples were
removed at various time points during the induction and then examined by
SDS-PAGE (Figure 4.5). Protein induction was evident by 1.5 hours and was
complete by 3 hours. The 22 kD apoE isoforms were produced in a much
greater quantity than any other protein produced by the host cell.
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Figure 4.4 DNA gel electrophoresis of the apoE2 (lanes 2, 3, and 4), apoE3
(lanes 5, 6, and 7), and apoE4 (lanes 8, 9, and 10) 22 kD plasmids with no cuts
(lanes 2, 5, and 8), one cut (lanes 3, 6, and 9) and two cuts (lanes 4, 7, and 10).
Lane 1 is a 123 DNA base-pair ladder standard. The arrow indicates the
excised 570 base-pair fragment.
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Figure 4.5 SDS-PAGE under reducing conditions of IPTG inductions of the 22
kD apoE isoforms at various time points. (A) apoE2: t=O hr (lane 2), t=1.5 hr
(lane 3), and t=3 hr (lane 4); (B) apoE3: t=0 hr (lane 2) and t=3 hr (lane 3); and
(C) apoE4: t=0 hr (lane 2), t=1.5 hr (lane 3), and t=3 hr (lane 4). Lane 1 in each
case is a 10 kD protein ladder standard.
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Purification of the 22 kD ApoE Isoforms
The apoE proteins were lysed and genetic material was precipitated
from the lysate by streptomycin sulfate. A large quantity of undesired protein
was then precipitated from the crude protein solution by ammonium sulfate.
SDS-PAGE confirmed that little apoE was lost from these steps. The protein
solution was then purified by size-exclusion chromatography. Most of the
protein impurities were efficiently separated from the apoE proteins after this
step (Figure 4.6). After the apoE peaks were isolated, dialyzed, and
lyophilized, they were further purified by ion-exchange chromatography. A
pure protein was isolated after the ion-exchange step, as visualized by SDS-
PAGE (Figure 4.7).
Inhibition of 3 Protein Amyloid Formation by the 22 kD Domain
The 22 kD Domain is an Effective Amyloid Inhibitor
The aggregation of the 3 protein under stirred conditions demonstrates
a protracted lag time as measured by turbidity. The addition of a 1% molar
equivalent of the N-terminal 22 kD domain of apoE3 (800 nM) to a
supersaturated solution of P1-40 (80 gM) resulted in a significant increase in
the lag time prior to aggregation (Figure 4.8). However, the C-terminal 10 kD
domain at a 1% molar equivalent (800 nM) had no activity under the same
conditions.
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Figure 4.6 SDS-PAGE under reducing conditions of three peaks (lanes 2, 3,
and 4 for each panel) collected after size-exclusion chromatography of apoE2
(A), apoE3 (B), and apoE4 (C). In each panel lane 1 is a 10 kD protein ladder
standard and apoE was isolated in peak 2 (lane 3).
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Figure 4.7
apoE4 (C)
Lane 1 for
SDS-PAGE under reducing conditionsof apoE2 (A), apoE3 (B), and
isolated by ion-exchange chromatography (lane 2 for each panel).
each panel is a 10 kD protein ladder standard.
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Figure 4.8 Aggregation of 31-40 (80 iM) in the presence of 1% of the apoE
proteolytic N- and C-terminal fragments under stirred conditions.
Inhibition of #f Protein Aggregation by 2% 22 kD apoE Isoforms
The aggregation of the 0 protein was examined in the presence of a 2%
molar equivalent of the 22 kD apoE2, apoE3, and apoE4 fragments in order to
determine differences in inhibitory activity at higher apoE concentrations
(Figure 4.9). However, the addition of 2% of the apoE proteins to a
supersaturated solution of 31-40 (80 gM) resulted in inhibition of aggregation
for more than 24 hours.
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Figure 4.9
apoE3, and
Aggregation of 01-40 (80 jgM) in the presence of 2% 22 kD apoE2,
apoE4 under stirred conditions.
Inhibition of Amyloid Formation is Very Sensitive to ApoE Concentrations
The sensitivity of P protein aggregation to the concentration of the 22
kD apoE isoforms was tested. Stirred kinetic experiments in the presence of
varying amounts of the 22 kD apoE3 protein were performed. The results in
Figure 4.10 demonstrate that aggregation can be inhibited in the presence of as
little as 0.5% of protein in a supersaturated solution of 31-40. Interestingly,
the longer that the aggregation of P1-40 is inhibited (i.e. larger percentages of
apoE present), the lower the final turbidity.
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Figure 4.10 The aggregation of 01-40 under stirred conditions is sensitive to
the concentration 22 kD apoE3 present.
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Inhibitory Activities of ApoE3 and ApoE4 are not Distinguishable
The 22 kD isoforms were tested in a stirred aggregation assay with P1-40
in order to distinguish whether or not they possessed different inhibitory
activities. When 1% molar equivalent of apoE3 or apoE4 was added to a
supersaturated solution of 80 pgM P1-40, protracted lag times were observed.
However, the lag times resulting from the addition of the two isoforms were
identical (Figure 4.11).
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Figure 4.11 Aggregation of 80 gM 031-40 in the presence of 1% molar
equivalent of 22 kD apoE3 or apoE4.
Creation of a 19 kD Truncated ApoE Protein
A 19 kD N-terminally truncated mutant of the 22 kD domain was also
expressed in E. coli. The truncation was achieved through the use of the Polymerase
Chain Reaction (PCR). The first truncated protein to be synthesized was C-
terminally truncated and comprised amino acids 1-165. Primers were designed to
produce a DNA insert that began at nucleotide 1 and ended at 495 of the 22 kD apoE
sequence (Figure 4.12). A flanking primer for the 5' end and an internal primer for
the 3' end was used to amplify a DNA insert corresponding to this
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Figure 4.12 Translation of cDNA from the 22 kD apoE3 seauence.
AAG GTT GAA CAG
TTC CAA CTT GTC
K V E Q
60
GAG TGG
CTC ACC
E W
20
CAG AGC GGC
GTC TCG CCG
Q S G
120
CGC TGG GTG CAG ACA
GCG ACC CAC GTC TGT
R W V Q T
40
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GCT GTT GAA
CGA CAA CTT
A V E
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Q R W
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L S E
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T Q E L R A
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E L
CAG GTG
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Q V
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CTG CTC
D E
CCG GTG
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P V
CGG CTG
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R L
GTG CAG
CAC GTC
V Q
CTG CGC
GAC GCG
L R
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GCC GAT GAC CTG CAG AAG CGC CTG GCA GTG
CGG CTA CTG GAC GTC TTC GCG GAC CGT CAC
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P E P
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CTC GAC GCG GTC GTC TGG
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L L S S Q V
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GAG TTG AAG
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E L K
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E T R
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CTG
D
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A Y K
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GCA CGG CTG
CGT GCC GAC
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L G Q S T
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AGG
S
GGC
CCG
G
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E E
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CGG CCC CGG
A G A
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R E G A
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L S A
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sequence. This insert was then spliced into a pET plasmid which was
subsequently transformed into BL21 cells.
The inserted restriction sites in the plasmid were checked by enzymatic
digestion of the DNA with NdeI (5' end) and BamHI (3' end) restriction
nucleases. By setting up reactions with either no cuts (no enzyme), one cut
(BamHI only), and two cuts (both enzymes) it was possible to confirm the
existence of the correct restriction sites. After the plasmid was cut with two
enzymes, a small DNA fragment running close to the 492 base pair marker
was liberated, indicating the correct restriction sites (Figure 4.13). The
calculated number of nucleotides that should be present in the insert is 507
nucleotides. The coding sequence of the purified insert was confirmed by
DNA sequencing using an ABI sequencer.
The insert coding for the 19 kD apoE protein was transformed into E.
coli BL21 cells and protein expression was induced by the addition of IPTG.
Figure 4.14 illustrates that protein production is complete after 1.5 hours, as is
observed by SDS-PAGE. The protein was purified using both size-exclusion
chromatography and ion-exchange chromatography (Figure 4.14).
Inhibition of P Protein Aggregation by a 19 kD Truncated ApoE
The aggregation of p1-40 under stirred conditions was tested in the
presence of a 19 kD truncated variant that ends at position 165 of apoE3. The
addition of 1% of the 19 kD variant extended the lag time significantly from
that of p1-40 alone. Furthermore, the presence of 2% of the 19 kD variant in a
supersaturated solution of 80 gM P1-40 resulted in an inhibition of fibril
formation past 24 hours, as is shown in Figure 4.15.
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Figure 4.13 DNA gel electrophoresis of the restriction digest of plasmids
containing the truncated apoE sequence isolated from three colonies (colony
1: lanes 2 and 3, colony 2: lanes 4 and 5, and colony 3: lanes 6 and 7). Lanes 2,
4, and 6 show the uncut plasmids, and lanes 3, 5, and 7 show the plasmids
with two cuts and a liberated DNA fragment. Lane 1 is a 123 DNA base-pair
ladder standard. The arrow indicates the excised 507 base-pair fragment.
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Figure 4.14 SDS-PAGE under reducing conditions of the IPTG induction
of the 19 kD protein (A) where lane 2 is t=0 hr and lane 3 is t=3 hr; of the
S300 purification (B) where lane 2 is peak 2; and of the pure protein (C)
where lane 2 is the protein after ion-exchange chromotagraphy. Lane 1 of
each gel is a 10 kD protein ladder standard.
400
20 __
1 2 3
30
20 ~
10
12
30
20 -A
10
12
149
Fc-I
i 40
Figure 4.15 Aggregation of 80 iM 31-40 in the presence of the 19 kD truncated
variant of apoE3.
The Cys57 22 kD ApoE3 Appears to Have Diminished Inhibitory Effects
A mutant of the 22 kD apoE3 protein in which a threonine at position
57 is replaced by a cysteine was obtained from Karl Weisgraber at the
Gladstone Institute (UCSF). This protein contains two cysteines and is
proposed to contain an intramolecular disulfide bond between Cys57 and
Cys112 that connects two of the helices in the four-helix bundle, preventing it
from opening. This mutant protein has been shown to possess a lower
affinity for lipid, as was previously discussed, supporting the theory that the
bundle must open in order to bind lipid.9
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The effect of the Cys57 mutant on the aggregation of 01-40 was
examined. In the presence of a 2% molar equivalent of the Cys57 mutant,
very little change in the lag time was observed, unlike the other apoE
proteins previously described (Figure 4.16). However, aggregation was
significantly delayed in the presence of a 4% molar equivalent. This indicates
that the Cys57 mutant is a less efficient inhibitor of amyloid formation,
possibly due to an intramolecular disulfide bond.
Figure 4.16 Aggregation of 01-40 (80 jgM) in the presence of the
Cys57 22 kD apoE3 mutant.
SDS-PAGE of the Cys57 mutant under reducing and non-reducing
conditions are identical (Figure 4.17). This does not reveal the actual state of
the intramolecular disulfide in either of the conditions since they would
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Figure 4.17 SDS-PAGE of the 22 kD Cys57
apoE3 mutant under non-reducing (lane 2)
and reducing (lane 3) conditions. Lane 1 is
a 10 kD protein ladder standard
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appear identical on a denaturing gel. However, it does indicate that neither
cysteine is forming an intermolecular disulfide bond.
Fibril Morphology May be Altered in the Presence of the 22 kD ApoE3
EM results from chapter 3 indicated that there was no difference in
morphology between amyloid fibrils produced in the absence and presence of
1% inhibitory concentrations of apoE3 or apoE4. However, other studies have
reported that preparations of amyloid fibrils formed in the presence of apoE
showed a greater number of fibrils as viewed by EM.14,15 Several studies that
examined the effect of apoE on either the aggregation of the 3 protein or the
morphology of the fibrils are compared in Table 4.1. The significant
differences in the experimental conditions and analytical techniques of each
study might explain the different results that each group reported.
When samples from the experiment in Figure 4.9 were viewed by
Atomic Force Microscopy (AFM), morphological differences were observed.
The 01-40 fibrils were shorter than the fibrils formed with apoE and were
fewer in number. The discrepancy between the results presented above and
those in chapter 3 could be due to differences in procedure or technique.
Further studies are required to rule out experimental artifacts.
If the aggregation mixture containing only 31-40 does contain fewer
fibrils than the solution with apoE, but reaches a much larger turbidity, then
the turbidity assay may not be measuring just fibrillar aggregates. The apoE
could be inhibiting one type of aggregation while promoting another.
Furthermore, the formation of amyloid fibrils and the consolidation of these
fibrils into amyloid plaques may involve different mechanisms. ApoE may
inhibit the formation of amyloid fibrils while causing these fibrils, once they
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do form, to clump together into plaques that are different from those formed
without apoE (Figure 4.18).
Figure 4.18 Proposed effect of apoE on both the nucleation phase of fibril
formation and on the formation of plaques by the amyloid fibrils.
Circular Dichroism of 22 kD ApoE Proteins
CD, which was discussed in detail in chapter 2, is a useful tool for
studying the conformation of proteins and peptides. The conformations of
several apoE isoforms were studied using this technique. In addition to the
three 22 kD polymorphic proteins, apoE2, apoE3, and apoE4, the 19 kD apoE3
truncated variant and a Cys57 apoE mutant were also analyzed. The apoE
proteins were analyzed at a concentration of 5 gM in 20 mM phosphate
buffered saline at 250C. Because of their highly helical nature, no organic
solvent such as TFE or HFIP was required to induce structure. All data is
reported in molar ellipticity. The percent a-helicity was determined from the
CD data as it was in chapter 2, using the method of Greenfield and Fasman for
the 208 nm absorption16 and the method of Morrisett for the 222 nm
absorption.17
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The 22 kD ApoE Isoforms Have a Large a-Helical Content
The isoforms were initially studied in buffer alone. The proteins
contain a large amount of a-helix at both 208 and 222 nm, and appear to have
almost identical conformations. Figure 4.19 shows the CD spectra of the
polymorphic 22 kD apoE isoforms, the 19 kD truncated variant, and the Cys57
22 kD apoE3 mutant. The amount of a-helix present in each of the proteins is
given in Table 4.2.
Stability Studies of the ApoE Proteins
The 22 kD domain of apoE is unusually stable when compared to other
apolipoproteins and exists as a four-helix bundle. If the opening of this four-
helix bundle to yield a hydrophobic and hydrophilic face is important for the
function of the protein, then differences in the stability of the bundle could be
critical in determining the effectiveness of these isoforms in the delivery of
hydrophobic molecules. CD was used to probe the stability of the 22 kD apoE
isoforms. Differences in the structural stability may be important in
modulating the effect of apoE in vivo.
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Figure 4.19 CD of 5 gM 22 kD apoE proteins and the 19 kD and Cys57
variants in buffer only.
Table 4.2 Percent cx-helicity of the apoE isoforms at 208 and
222 nm.
ApoE Isoform 208 nm 222 nm
22 kD Cys57 88 78
22 kD apoE2 78 76
22 kD apoE3 73 71
22 kD apoE4 88 80
19 kD apoE3 89 81
157
' I I l lI l I | I I I I
* 22 kD Cys57
S19 kD variant
tO · 22 kD apoE2
° 22 kD apoE3
+ 22 kD apoE4
SI I I I I i I I
UV,VVVUU
40,000
20,000
E
-o
E 0
-20,000
-40,000
4n AM
195 200 205 210 215 220 225 230 235 240 245 250
Wavelength (nm)
LI| " "'1 ...
22 kD Cys57 ApoE3
Figure 4.20 shows the CD spectra of the Cys57 mutant in the presence of
1 mM DTT, 1 M GuHC1, and 3 M GuHC1. The two GuHCl concentrations
correspond roughly to the two conformational transitions found in the full-
length protein (discussed in chapter 3). The spectra of the proteins in the
presence of 3 M GuHCI are scattered below 210 nm due to the large absorbance
of the GuHCl in this region, therefore, a-helicity was not calculated at 208 nm
for the 3 M GuHC1 spectra (Table 4.3).
Figure 4.20 CD of 5 gM 22 kD Cys57 apoE3 alone and in the
presence of 1 mM DTT, 1 M GuHC1, and 3 M GuHC1.
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Table 4.3 Percent a-helicity of 5 p.M 22 kD Cys57 apoE3.
208 nm 222 nm
22 kD Cys57 88 78
1 mM DTT 92 78
1 M GuHC1 78 80
3 M GuHC1 NA 45
22 kD ApoE Isoforms
The CD spectra of 22 kD fragments of apoE2, apoE3, and apoE4 alone
and in the presence of 1 mM DTT, 1 M GuHC1, and 3 M GuHCI are shown in
Figures 4.21, 4.22, and 4.23. The percent a-helicity of each are shown in Tables
4.4, 4.5, and 4.6.
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Figure 4.21 CD of 5 gM 22 kD apoE2 alone and in the presence
of 1 mM DTT, 1 M GuHC1, and 3 M GuHC1.
Table 4.4 Percent cx-helicity of 5 gM 22 kD apoE2.
208 nm 222 nm
22 kD apoE2 73 71
1 mM DTT 63 59
1 M GuHCl 70 66
3 M GuHCl NA 23
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Figure 4.22 CD of 5 gM 22 kD apoE3 alone and in the presence
of 1 mM DTT, 1 M GuHC1, and 3 M GuHC1.
Table 4.5 Percent ox-helicity of 5 jiM 22 kD apoE3 .
208 nm 222 nm
22 kD apoE3 88 80
1 mM DTT 92 80
1 M GuHCl 100 87
3 M GuHC1 NA 22
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Figure 4.23 CD of 5 gM 22 kD apoE4 alone and in the presence
of 1 M GuHC1 and 3 M GuHC1.
Table 4.6 Percent a-helicity of 5 gM 22 kD apoE4.
208 nm 222 nm
22 kD apoE4 89 81
1 M GuHC1 77 70
3 M GuHC1 NA 26
19 kD ApoE3 Truncated Variant
The CD spectra for 5 gM 19 kD apoE3 truncated variant are shown in
Figure 4.24 and the percent a-helicity is given in Table 4.7.
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Figure 4.24 CD of 5 gM 19 kD apoE3 variant alone and in the
presence of 1 mM DTT, 1 M GuHC1, and 3 M GuHC1.
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Table 4.7 Percent a-helicity of 5 pM 19 kD apoE3 variant.
208 nm 222 nm
19 kD mutant 78 76
1 mM DTT 72 65
1 M GuHC1 93 84
1 M GuHC1 NA 22
The Cys57 Mutant Appears to be More Stable
There was not a significant change in the percent a-helicity of any of
the apoE isoforms either in the presence of either 1 mM DTT or 1 M GuHC1,
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which is in agreement with previously published reports.18 However, one
isoform, the Cys57 mutant, showed a smaller effect from the 3 M GuHC1 than
any of the other proteins. Figure 4.25 shows the spectra of the five proteins in
the presence of 3 M GuHC1 between 195 and 250 nm and the percent a-helicity
for the 222 nm absorption is given in Table 4.8. The spectra are scattered
below 210 nm due to the large absorbance of GuHCl in this region. The Cys57
protein shows a 33% decrease in a-helicity in the presence of 3 M GuHCl
while the other proteins show decreases of 48 to 59%.
Figure 4.25 CD spectra of the apoE proteins in the presence of 3 M
GuHC1.
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Table 4.8 Decrease in percent x-helicity
of the apoE proteins in the presence of
3 M GuHC1.
ApoE Protein 222 nm
22 kD Cys57 33
22 kD apoE2 48
22 kD apoE3 58
22 kD apoE4 59
19 kD variant 48
Discussion
In chapter 3, the ability of apoE to inhibit aggregation of the 3 protein
into amyloid fibrils was described and the role of apoE in the pathogenesis of
AD was examined. The studies presented herein narrow the region
responsible for the inhibitory activity of the protein down to the 22 kD
domain. The three polymorphic isoforms of the 22 kD domain of apoE
(apoE2, apoE3, and apoE4) were expressed in E. coli and the recombinant
proteins were purified and used in vitro to test their ability to inhibit 0
protein aggregation. A 19 kD apoE3 truncated protein was also expressed and
purified.
The results show that the 22 kD domain of apoE, like the full-length
protein, is an effective inhibitor of amyloid formation at a 0.5% molar
equivalent. Interestingly, very small changes in the amount of the 22 kD
domain have very large effects on the lag time of the P protein. A
supersaturated solution of 31-40 containing 2% of a molar equivalent of
either apoE2, apoE3, or apoE4 inhibit aggregation past 24 hours. Additionally,
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the final turbidity of aggregated solutions of P1-40 with more than a 1% molar
equivalent of apoE is lower than solutions without the apoE. While low
levels of apoE do not appear to affect the growth and stability of fibrils, higher
concentrations of proteins may have an effect.
The concentration dependence of apoE that was exhibited in the
aggregation assay can be explained by the nucleation-dependent model of
amyloid formation in which apoE is binding to a large oligomer of P1-40. In
this mechanism, very small increases in the amount of apoE present would
result in a much larger sequestration of P1-40. This would decrease the
effective concentration of 31-40 in solution and could result in a lag time that
is longer than 24 hours for experiments with a 2% molar equivalent of apoE.
Results by Ronald Wetzel and coworkers confirm the work presented
above. They have also shown that the aggregation of the 3 protein can be
described by a nucleation-dependent mechanism and that apoE is an effective
inhibitor of 31-40 aggregation. 19 In addition, they have isolated a high
molecular weight complex with an apoE:3 protein ratio of 1:95. This complex
provides evidence that a small amount of apoE can bind to large 31-40
oligomers.
While both the apoE3 and apoE4 22 kD proteins extended the lag time
in the aggregation of 11-40, no difference in inhibitory activity was observed.
These results are similar to those produced from the full-length proteins.
However, because the apoE protein concentrations are measured by the Lowry
test, which can have a significant margin of error, it is very difficult to
measure precisely the amount of protein added to the 31-40. This makes
comparisons between different isoforms problematic due to the sensitivity of
the assay to the apoE concentration.
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The 19 kD truncated variant behaved similarly to the 22 kD proteins in
that a 1% molar equivalent of the protein produced a significant increase in
the lag time. The truncated protein also inhibited the aggregation of the 03
protein past 24 hours when present at 2%. Therefore, the deleted C-terminal
portion of the 22 kD domain that exists as a random coil does not appear to be
important to the inhibitory function of the protein.
The proteins were also examined by CD in order to compare their
structures and relative stability. At a concentration of 5 jRM without the
addition of nonpolar helix-inducing solvents the protein contained very large
amounts of a-helix (73 to 89%). The proteins were also monitored in the
presence of 1 mM DTT, 1 M GuHC1, and 3 M GuHC1. There were no
significant changes in conformation in the presence of 1 mM DTT or 1 M
GuHC1. These results are in agreement with previous results showing the 22
kD domain to be unusually stable, up to a concentration of 2.4 M GuHC1.
Large changes in a-helicity of all of the variants were observed in the
presence of 3 M GuHC1. However, an apoE3 mutant containing a Cys57
mutation showed a smaller decrease in helicity and therefore appeared to be
more stable than the other variants. This variant has been shown to have a
lower affinity for lipid molecules.
Future Directions
Aggregation conditions that can distinguish between the inhibitory
abilities of the apoE variants, if they do exist, should be developed. More
truncated forms of the 22 kD domain of apoE should also be produced until
the protein no longer possesses inhibitory activity. Variants that are N- and
C-terminally truncated and that contain only one, two, or three a-helices
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should be tested. Furthermore, a synthetic four-helix bundle in which all
four of the helices are identical and joined by linkers could be useful in
determining whether or not the four-helix bundle motif alone is sufficient
for inhibition. The truncated proteins could also be examined by CD in order
to determine their relative stabilities.
Further studies of the effect of apoE concentration on the aggregation
and morphology of the amyloid fibrils should be completed. Specifically, the
following AFM experiments could be performed to determine if the presence
of apoE simply helps the fibrils adhere to the AFM surface, leading to the false
conclusion that more fibrils are formed in the presence of apoE:
1) make p1-40 fibrils with no apoE, view by AFM
2) make 31-40 fibrils, then add apoE, view by AFM
3) make j1-40 fibrils with apoE, view by AFM
The effect of lipids on the ability of apoE to inhibit the aggregation of
01-40 should be examined using the turbidity assay. The experiments
described were run using apoE that was not bound to lipid, which may not be
biologically relevant as apoE is never isolated from plasma in its lipid-free
form. Aggregation experiments containing relevant concentrations of lipid
should be performed to determine the ability of P protein oligomers to
displace the lipid. Additionally, the effect of lipids on the morphology of
fibrils formed in the presence of apoE could be examined by AFM.
Most importantly, the development of an assay that could measure the
aggregation of the 0 protein more accurately and reproducibly than the
turbidity assay would be extremely useful. One factor that would greatly
improve the assays is the creation of a stock solution of 31-40 that would not
"age". When the stock solution ages, it produces protein solutions that
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aggregate faster than previous runs, possibly due to the creation of small
nuclei.
Experimental
Materials
Expression vectors for the apoE2, apoE3, and apoE4 proteins, as well as
the purified Cys57 mutant protein were obtained from Dr. Karl Weisgraber at
the Gladstone Institute (UCSF). The pET expression plasmid was purchased
from Novagen. The Lowery protein assay kit was purchased from Pierce.
IPTG was obtained from Boehringer Mannheim. Reagents used for cell
growth (Yeast Extract, Tryptone, and Agar) were all purchased from Difco.
GuHCl were obtained from Mallincrodt. S-300 size-exclusion beads were
purchased from Pharmacia. Ultra Pure Agarose (low melting-point) was
purchased from GibcoBRL. The deoxynucleotides were obtained from New
England Biolabs. Oligonucleotides were purchased from Midland and
enzymes were obtained from New England Biolabs. Aerosol resistant tips
were obtained from USA Scientific. DEAE columns were purchased from
Waters.
Aggregation Assay (Stirred)
Aggregation was monitored at 400 nm using the turbidity assay. Stock
solutions were prepared and experiments were performed as previously
described in Chapter 3. Results with the 19 kD apoE3 are based on one
experiment.
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Preparation of Competent Cells
Overnight cultures (inoculated with a glycerol stock prepared from a
single colony of either DH1 or BL21 cells) were grown in 10 ml of L-broth
media (10 g tryptone, 10 g NaCl, 5 g yeast extract, dissolved to 1000 ml)
containing no ampicillin at 370C in a shaking incubator. The 10 ml culture
was then used to inoculate 1 L of L-broth in 4 L flask and was shaken at 370C
until the OD 550 was 0.5 to 0.6. The culture was rapidly chilled to 40C by
swirling in an ice/water bath. The cells were harvested in pre-chilled
centrifuge bottles and were spun at 5000 rpm for 5 minutes in a Beckman
centrifuge (model J2-21) with a rotor cooled to 40C. During the remainder of
the procedure the cells were kept on ice or in a 40C cold room. The cell pellet
was resuspended in 250 ml ice-cold sterile-filtered 100 mM MgC12, initially
suspending the cells in a small volume (50 ml) and then diluting with the
remainder of liquid. The cells were spun down as above. The cell pellet was
then resuspended in 250 ml of ice-cold sterile-filtered 100 mM CaC12 as gently
as possible as the cells become very fragile in CaC12. The solution was
incubated on ice for 20-45 minutes. The cells were then spun at 3000 rpm for
5 minutes. The cell pellet was then gently resuspended in 50 ml of ice-cold
sterile freezing medium (42.5 ml 100 mM CaC12, 7.5 ml glycerol). The cells
were dispensed in 300 p1 aliquots into Eppendorf tubes and frozen rapidly in a
dry ice/EtOH bath. The aliquots were stored at -800C.
Purification of Plasmid DNA
Overnight cultures (5-10 ml) of E. coli, either DH1 or BL21 strains, were
grown as described above, with the exception that ampicillin was added to the
L-broth (100 gg/ml). The cells were transformed into Eppendorfs and pelleted
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by centrifugation for approximately one minute. The plasmid DNA was then
isolated and purified using the QIAGEN Spin Plasmid Kit according to the
specified protocol. The DNA was eluted with either water or 10 mM Tris-HCI
pH 7.4 (30-50 •l).
Transformation of E. coli
Frozen competent cells were thawed on ice. Competent cells (100
pl/transformation) were aliquoted into pre-chilled sterile Falcon 2059 tubes
on ice using sterile technique. For each transformation a positive control
(cells transformed with a known amount of purified plasmid to test the
competency of the cells) and a negative control (cells with no added DNA to
test the purity of the cells) were also performed. The DNA (5-10 ng) was
added to the chilled tubes and the cells were swirled gently to mix. For
transformations using a ligation mixture in which DNA has been ligated into
an expression vector (see below for ligation procedure) an additional control
was performed. The empty dephosphorylated plasmid (the cut vector
without the DNA PCR insert) was added to the competent cells. The tubes
were then incubated on ice for 30-60 minutes. After the incubation, the cells
were heat shocked by placing the tubes in a 420C heat bath for exactly one
minute. The cells were cooled on ice for 30 seconds and then placed at room
temperature. SOC medium (900 •l) pre-heated to 420C was added to each tube
which was shaken gently on a rotating platform at 370C for 15-60 minutes.
The cells were then spread onto ampicillin plates (no more than 300 p• of
transformation mixture per plate), allowed to dry, and incubated upside down
at 370C overnight.
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MgCl/MgSO4 solution: 12.0 g MgSO4-7H20
9.5 g MgC12
Dilute to 100 ml and sterile filter
SOC medium: 4 g tryptone
1 g yeast extract
0.1 g NaCl
4 ml 20% glucose
2 ml MgC12/MgSO4 solution
Dilute to 200 ml and autoclaved
Protein Induction
Cultures of BL21(DE3) cells containing the apoE plasmids were grown
as described for the production of competent cells above, with the exception
that all L-broth medium used contained ampicillin (100 gg/ml). The cultures
were grown until they reached an OD550 of 0.5 to 0.6. At this point 1 ml of
culture was removed for later analysis by SDS-PAGE. IPTG was then added to
the culture to give a final concentration of 0.5 mM and the cells were shaken
at 370C for three hours. A sample (1 ml) of culture was removed at 1.5 hours
and 3 hours to be analyzed by SDS-PAGE. After protein expression was
completed, the cells were harvested at 9000 rpm using a Beckman J2-21
centrifuge. The cell pellets were stored at -200C. The cell pellets were
dissolved in 1x lysis buffer (50 mM Tris pH 7.4, 100 p.M DTT, 100 [LM PMSF,).
The cells were disrupted by passage through a French pressure cell at 16,000
psi, keeping the cells on ice throughout the procedure, and the cell lysate was
then spun at 9,000xg for 35 minutes. Streptomycin sulfate (0.2 volumes of a
5% solution) was added to the supernatant which was stirred at 40C for 30
minutes and then spun at 9,000xg for 20 minutes. Ammonium sulfate was
added to the supernatant to yield a 60% solution, the solution was stirred at
40 C for 1 hour, and was then centrifuged at 9,000xg for 20 minutes. The
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protein pellet was then dissolved in 1x lysis buffer and solid GuHC1 was
added to yield 15 ml of a 7 M GuHC1. OME was added to bring the solution to
1% PME. This crude protein solution was subsequently purified by size-
exclusion chromatography (see below).
PCR Protocol
The PCR mixture contained in a total of 100 pl: clean, quantitated
(A260) plasmid (1 ng to 100 ng), 1 pmol each of primer 1 and primer 2 (see
below), a mixture of all four deoxynucleotides (dATP, dGTP, dCTP, and dTTP)
at 100 gM each, 10 Cl of 10x PCR buffer (100 mM KC1, 200 mM Tris-HC1 pH 8.8,
100 mM (NH4)2SO4, 20 mM MgSO4, 1% Triton X-100), and 4 p• sterile filtered
DMSO, which was added to the PCR reactions in order to lower the effective
Tm of the DNA duplexes and is critical for amplifications involving the GC-
rich apoE gene. The mixture was overlaid with paraffin oil and heated at
940C for 3 minutes. The high fidelity Vent polymerase (2 U) was used instead
of Taq polymerase, which has a higher level of spurious mutation, and was
added under the oil layer. The tubes were then heated for 30 cycles according
to the following program: 940C (1 minute), 500C (1 minute), 750C (2 minutes).
Aerosol resistant tips were used for all amplifications in order to prevent
contamination of the solutions. All PCR reactions were performed in 0.5 ml
Eppendorf tubes. For each PCR reaction, a control reaction was also
performed in which no template was added in order to check for
contamination in the reagents.
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Primer 1 (5' to 3')
AAA GGA AGA GTA TGC ATA TGA AGG TTG AAC AGG
NdeI
Primer 2 (5' to 3')
ATT GGA TCC TTA CCG CAC GCG GCC CTG TTC
-• V
BamHI
Synthesis of Truncated ApoE DNA Inserts
In order to make truncated variants of 22 kD apoE3, primers 3 and 4,
corresponding to internal sequences of apoE, were designed and purchased
from Midland (see below). All PCR was performed as described above, except
the truncated primers were used in place of or with the flanking primers
described above.
Primer 3 (5' to 3')
AAA GGA AGA GTA TGC ATA TGG GCC AGC GTC GGG A
NdeI
Primer 4 (5' to 3'Y
ATT GGA TCC TTA GCC CTG GTA CAC TGC CAG
BamHI
Purification of PCR Products
Purification of the products from the PCR reaction was required before
digestion. All PCR material was purified using the QIAGEN PCR Purification
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Kit according to the specified protocol. The DNA was eluted from the
column with H20 (30 to 50 •l).
Restriction Digest of DNA
For each plasmid, the digest contained the following in a total volume
of 10 to 15 •l: NdeI (10 U), BamHI (20 U), and 1 pl of 10x BamHI buffer (1.5 M
NaC1, 100 mM Tris-HC1, pH 7.9, 100 mM MgCl2, 10 mM DTT). Each tube was
diluted to the final volume (10-15 •l) with H20. The samples were incubated
in a heated water bath at 370C for 1 to 1.5 hours. DNA material that was to
later to be used in a ligation reaction was gel purified, the DNA band was
excised from the gel using a new razor blade, and the DNA was purified using
the QIAGEN Gel Purification Kit. DNA was eluted from the columns with
H20 (50-100 p1). For all other digests, the restriction digest was analyzed by gel
electrophoresis. The 1% agarose gels contained 1% ethidium bromide, and
DNA was visualized by UV light.
Ligation of PCR Insert and Vector
Prior to ligation, the pET vector (0.1 gg) was enzymatically digested as
described above. In a total volume of 60 pl, the digested pET vector was then
dephosphorylated with shrimp alkaline phosphatase (0.1 U) that contained 6
•l of 10x phosphatase buffer (200 mM Tris-HC1, pH 8.0, 100 mM MgC12)
according to the specified protocol in order to prevent the cut plasmid from
reclosing on itself. The mixture was incubated at 370C for 2.5 hours. The
mixture was then heated at 650C for an additional 15 minutes in order to
denature the enzyme. The ligation mixture contained the following in a total
volume of 120 pl: 50 •l of the dephosphorylated pET vector mixture, 55 •l of
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the gel-purified PCR insert (described above), 12 pl of 10x T4 ligase buffer (500
mM Tris-HC1, pH 7.8, 100 mM MgC12, 100 mM DTT, 10 mM ATP, and 500
Cgg/ml BSA), and T4 ligase (400 U). The solution was incubated overnight at
160C. The ligation mixture was then transformed into either DH1 or BL21 E.
coli cells (see above).
Purification of 22 kD apoE
Size-Exclusion Chromatography
The crude protein in 7 M GuHCl, which was prepared in the "Protein
Induction" section described above, was purified using a size-exclusion
column (92 X 4 cm) containing S-300 beads packed in 4 M GuHC1 solution (4
M GuHCl, 1 mM EDTA, 0.1 M Tris, pH 7.4, 0.1 % PME). The column was
equilibrated with 500 ml fresh 4 M GuHC1 solution prior to use. The protein
sample (15 ml in 7 M GuHCl (1% PME)) was added slowly to the column by
gravity over 15 minutes and fractions were collected (15 minutes per tube)
and analyzed at 280 nm. The fractions comprising each peak were combined,
transferred into dialysis tubing with a 6-8 MW cut off (Sigma), and dialyzed 5x
over 3 days at 40C in 20 mM ammonium bicarbonate. The protein solutions
were lyophilized and the correct protein was identified by SDS-PAGE.
Ion-Exchange Chromatography
The apoE proteins (5 mg) initially purified by size-exclusion
chromatography (above) were dissolved in 20 mM Tris-HCl at pH 7.4 (700 Il)
to yield a cloudy solution. Urea (600 pl of a 9.8 M solution) was then added,
resulting in clear solution. DTT was added (10.2 mg) and the solution was
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centrifuged briefly to pellet any remaining insoluble material. The proteins
were purified by HPLC using an analytical (7.5 X 75 mm) or semi-preparative
(21.5 X 150 mm) DEAE ion-exchange column, according to the gradient
described below, with a flow rate of 1 ml/min monitored at 225 nm. The
isolated protein was dialyzed in 20 mM ammonium bicarbonate 3x at 40C,
lyophilized, and analyzed by SDS-PAGE.
DEAE Gradient (bufferA/buffer B):
100/0 2'a-75/25 10'a-0/100 "'-100/0
Buffer A: 20 mM Tris-HCl
Titrate to pH 7.4 and filter
Buffer B: 20 mM Tris-HC1
0.5 M NaCl
Titrate to pH 7.4 and filter
Circular Dichroism of Protein Samples
CD spectra were obtained using an AVIV spectrapolarimeter in the
laboratory of Dr. Paul Schimmel, Department of Biology, MIT. Stock
solutions of proteins were in 0.1 M NH4HCO 3. Protein concentrations were
determined using the Lowery protein determination kit. CD samples were
prepared by adding the stock protein solutions to either 20 mM PBS buffer
alone or buffer containing 1 mM DTT or buffer containing 1 mM DTT with
either 1 or 3 M GuHC1 to give a final protein concentration of 5 RtM. The
samples were incubated at room temperature overnight. Each sample was
scanned four times in a quartz cell (0.1 cm pathlength) at 0.5 nm intervals
over the wavelength range of 190 to 250 nm at 250C. Solvent and cell
backgrounds were subtracted from each sample. Results are expressed in
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terms of molar ellipticity in units of deg-cm 2 /dmol. No smoothing technique
was used to reduce noise levels.
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